Methodological development of molecular endotype discovery from synovial fluid of individuals with knee osteoarthritis: the STEpUP OA Consortium

Authors: Y.Deng^{**}, T.A.Perry^{**}, P.Hulley², R.A.Maciewicz², J.Mitchelmore³, D.Perry^{*}, S.Larsson³
S. Brachat³, A.Struglics⁵, C.T. Appleton⁶, S. Kluzek²⁷, N. K. Arden^{2,8}, D. Felson⁹, B.Marsden^{2,10}
 , S. Brachat", A.Struglics", C.T. Appleton", S. Kluzek^{4.}', N. K. Arden⁴¹⁰', D. Felson", B.Marsden⁴¹⁰',
B.D.M.Tom¹¹, L.Bondi¹¹, M. Kapoor¹², V.Batchelor¹, J. Mackay-Alderson¹, V.Kumar², L. S. Lohmander⁵,
T B.D.M.Tom¹¹, L.Bondi¹¹, M. Kapoor¹², V.Batchelor², J. Mackay-Alderson², V.Kumar², L. S. Lohmander⁵
T. J. Welting¹³, D. A. Walsh^{14,15}, A.M.Valdes¹⁴, the STEpUP OA Consortium, T. L. Vincent^{1#}, F. E. Wat ,
,
,

T. J. Welting²³, D. A. Walsh^{14,23}, A.M.Valdes²⁴, the STEpUP OA Consortium, T. L. Vincent²⁴, F. E. Watt^{20,14},
^{1#}, L. Jostins-Dean^{1#}
¹ Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institut ^{*"}, L. Jostins-Dean^{*"}
¹ Centre for Ostee
NDORMS, Universit
² Nuffield Departm[,] 1
|
(

² Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology,
NDORMS, University of Oxford, Oxford, UK.
² Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Parament of Orthopaedics, Rhendorf Control
Noxford, Oxford, UK.
A Novartis Institutes for Biomedical Research
A SomaLogic, Boulder, Colorado, USA. 2 Nufford, Oxford, UK.

Novartis Institutes for Biomedical Research, Basel, Switzerland.

SomaLogic, Boulder, Colorado, USA.

Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Lund University, Lund,

³ Novartis Institutes
⁴ SomaLogic, Boulde
⁵ Faculty of Medicir
Sweden. ⁹ Novartis Institutes for Biomedical Research, Basel, Switzerland.
⁴ SomaLogic, Boulder, Colorado, USA.
⁵ Faculty of Medicine, Department of Clinical Sciences Lund, O
Sweden.
⁶ Bone and Joint Institute, University ⁵ SomaLogic, Boulder, Colorado, USA.
⁵ Faculty of Medicine, Department o
Sweden.
⁶ Bone and Joint Institute, University c
⁷ NIHR Nottingham Biomedical R .
أ

Faculty of Medicine, Department of Clinical Sciences Lundy Sciences Lund University, Lundy, 2006.
Bone and Joint Institute, University of Western Ontario, London, Ontario, Canada.
NIHR Nottingham Biomedical Research Centre ⁶ Bone an
⁷ NIHR
Osteoartl
⁸ Centre ⁸ Bone and Joint Institute, University of Western Ontario, London, Ontario, Canada.
⁷ NIHR Nottingham Biomedical Research Centre and Versus Arthritis Spo
Osteoarthritis Centre, University of Nottingham, Nottingham, UK. \overline{a}

Disteoarthritis Centre, University of Nottingham, Nottingham, UK.
Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford,
Dxford, UK.
Section of Rheumatology, Boston University School ⁸ Centre for Sport, Exercise and Osteoarthritis Research Versu
Oxford, UK.
⁹ Section of Rheumatology, Boston University School of Medicine, ¹⁰ Nuffield Department of Medicine, University of Oxford, Oxford,

9 Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.
⁹ Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.
¹⁰ Nuffield Department of Medici

¹⁰ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹¹ MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
¹² Schroeder Arthritis Institute, University Health Network, Toronto, Ontario,

³ Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.
¹⁰ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹¹ MRC Biostatistics Unit, University of Cambridge, C ²⁰ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹¹ MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
¹² Schroeder Arthritis Institute, University Health Network, Toronto, O
¹³ La ¹¹ MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
¹² Schroeder Arthritis Institute, University Health Network, Torontc
¹³ Laboratory for Experimental Orthopedics, Department of
University, Maastricht ¹¹ Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
¹³ Laboratory for Experimental Orthopedics, Department of Orthopedic Surge
University, Maastricht, Netherlands.
¹⁴ Pain Centre Ve

University, Maastricht, Netherlands.
¹⁴ Pain Centre Versus Arthritis, Advanced Pain Discovery Platform, and the NIHR Nottingham
Biomedical Research Centre, University of Nottingham, Nottingham, UK.
¹⁵ Sherwood Forest H 14 Pain Centre Versus Arthritis, Ac
Biomedical Research Centre, Univers
¹⁵ Sherwood Forest Hospitals NHS Fo¹⁶
¹⁶ Department of Immunology and In ¹⁴ Pain Centre Versus Arthritis, Advanced Pain Discovery Platform, and the NIHR Nottingham
Biomedical Research Centre, University of Nottingham, Nottingham, UK.
¹⁵ Sherwood Forest Hospitals NHS Foundation Trust, Sutton

Biomedical Research Centre, University of Notema_n many computes
¹⁵ Sherwood Forest Hospitals NHS Foundation Trust, Sutton in Ashfield, U
¹⁶ Department of Immunology and Inflammation, Imperial College Londor
*Joint fi

¹⁵ Sherwood Forest Hospitals NHS Foundation Trust, Sutton in Ashfield, UK.
¹⁶ Department of Immunology and Inflammation, Imperial College London, I
*Joint first authors, [#]equal contributions. ¹⁹ Department of Immunology and Inflammation, Imperial College London, London, UK.
*Joint first authors, [#]equal contributions.

Corresponding author: Professor Tonia L Vincent (tonia.vincent@kennedy.ox.ac.uk), Dr Luke Jostins-
Dean (luke.jostins@kennedy.ox.ac.uk) and Dr Fiona Watt (fiona.watt@kennedy.ox.ac.uk), Centre for
Osteoarthritis Pathogenesi Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, University of

Keywords: biomarker, proteomic, synovial fluid, osteoarthritis, knee injury, endotype, stratification, Somalogic. over an allow of the series of the series of the series of the Somalogic.
Somalogic.
Somalogic.
Somaling title: Methods for m $\frac{1}{2}$ Keywords: biomarker, proteomic, synovial fluid, osteoarthritis, knee injury, endotype, stratification,
Somalogic.
Running title: Methods for molecular endotype discovery in STEpUP OA

Running titl_e Running title: Methods for molecular endotype discovery in STEpUP OA

ABSTRACT

Objectives: To develop and validate a pipeline for quality controlled (QC) protein data for largescale

Objectives: To develop and validate a pipeline for quality controlled (QC) protein data for largescale
analysis of synovial fluid (SF), using SomaLogic technology.
Design: Knee SF and associated clinical data were from p analysis of synovial fluid (SF), using SomaLogic technology.
 Design: Knee SF and associated clinical data were from partner cohorts. SF samples were

centrifuged, supernatants stored at -80°C, then analysed by SomaScan Design: Knee SF and associated clinical data were from partner cohorts. SF samples were
centrifuged, supernatants stored at -80°C, then analysed by SomaScan Discovery Plex V4.1 (>7000
SOMAmers/proteins).
Setting: An inte

centrifuged, supernatants stored at -80°
SOMAmers/proteins).
Setting: An international consortium of 9
Participants: 1746 SF samples from 165
and inflammatory arthritis controls. d Participants: 1746 SF samples from 1650 individuals comprising OA, joint injury, healthy controls Setting: An internation
Participants: 1746 SF
and inflammatory and
datasets. Setting: An international consortium or 9 academic and 8 commercial partners (STEPOP OA).

Participants: 1746 SF samples from 1650 individuals comprising OA, joint injury, healthy

and inflammatory arthritis controls, divi

Participants: 1746 SF samples from 1650 individuals compirising OA, joint injury, healthy controls
and inflammatory arthritis controls, divided into discovery (n=1045) and replication (n=701)
datasets.
Primary and secondar datasets.
 Primary and secondary outcome measures: An optimised approach to standardisation was

developed iteratively, monitoring reliability and precision (comparing coefficient of variation [%CV]

of 'pooled' SF sampl anderes
Pri**mary**
developed
of 'pooled
defined to
Poorly ne Primary and secondary outcome measures. An optimised approach to standardisation was
developed iteratively, monitoring reliability and precision (comparing coefficient of variation [%CV]
of 'pooled' SF samples between plat defined technical confounders were adjusted for (by Limma) and batch correction was by ComBat.
Poorly performing SOMAmers and samples were filtered. Variance in the data was determined by
principal component (PC) analysis. defined technical conforming SOMAmers and samples were filtered. Variance in the data was determined by
principal component (PC) analysis. Data were visualised by Uniform Manifold Approximation and
Projection (UMAP).
Resul

Results: Optimal SF standardisation aligned with that used for plasma, but without median Poorly performing Sommatic and samples in the instead can always an any principal component (PC) analysis. Data were visualised by Uniform Manifold Approximation and
Projection (UMAP).
Results: Optimal SF standardisation a projection (UMAP).
 Results: Optimal SF standardisation aligned with that used for plasma, but without median

normalisation. There was good reliability (<20 %CV for >80% of SOMAmers in pooled samples) and

overall good Projection (UMA).
 Results: Optimal S

normalisation. Ther

overall good corre

correlated with ind

could be adjusted. Results: Optimal SF standardisation aligned with that used for plasma, but without inculant
normalisation. There was good reliability (<20 %CV for >80% of SOMAmers in pooled samples) and
overall good correlation with immun overall good correlation with immunoassay. PC1 accounted for 48% of variance and strongly
correlated with individual SOMAmer signal intensities (median correlation coefficient 0.70). These
could be adjusted using an 'intra oorrelated with individual SOMAmer signal intensities (median correlation coefficient 0.70). These
could be adjusted using an 'intracellular protein score'. PC2 (7% variance) was attributable to
processing batch and was ba could be adjusted using an 'intracellular protein score'. PC2 (7% variance) was attributable to
processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other
technical confounders. Data visual processing batch and was batch-corrected by ComBat. Lesser effects were attributed to other
technical confounders. Data visualisation by UMAP revealed clustering of injury and OA cases in
overlapping but distinguishable ar procession and Confounders. Data visualisation by UMAP revealed clustering of injury and OA cases in
overlapping but distinguishable areas of high-dimensional proteomic space.
Conclusions: We define a standardised approa overlapping but distinguishable areas of high-dimensional proteomic space.
Conclusions: We define a standardised approach for SF analysis using the SOMAscan platform and

identify likely 'intracellular' protein as being a major driver of variance in the data.

Strengths and limitations:

• This is the largest number of individual synovial fluid samples analysed by a high content

Strengths and limitations:

 $\overline{}$ $\overline{}$ $\overline{}$ $\overline{}$ $\overline{}$ $\overline{}$ $\overline{}$ Ļ

- Conclusions: We define a standardised approach for SF analysis using the SOMAscan platform and

identify likely 'intracellular' protein as being a major driver of variance in the data.
 Conclusions:

This is the largest Strengths and limitations:

• This is the largest number of individual synovial fluid samples analysed b

proteomic platform (SomaLogic technology)

• SomaScan offers reliable, precise relative SF data following standardis •
	- •
	- proteomic platform (SomaLogic technology)

	SomaScan offers reliable, precise relative SF data following standardisation for over 6000

	proteins

	Significant variance in the data was driven by a protein signal which is like proteins
SomaScan offers reliable, precise relative SF
proteins
Significant variance in the data was driven b
in origin: it is not yet clear whether this is (
turnover or relevant pathological processes
Adjusting for confo Significant variance in the data was driven by a protein signal which is likely intracellular
in origin: it is not yet clear whether this is due to technical considerations, normal cell
turnover or relevant pathological pr proteins
Significant variance in the data was driven by a protein signal which is likely intracellular
in origin: it is not yet clear whether this is due to technical considerations, normal cell
turnover or relevant pathol • in origin: it is not yet clear whether this is due to technical considerations, normal cell
turnover or relevant pathological processes
Adjusting for confounding factors might conceal the true structure of the data and
red
	- Adjusting for confounding factors might conceal the true structure of the data and reduce the ability to detect 'molecular endotypes' within disease groups • reduce the ability to detect 'molecular endotypes' within disease groups

	And the true structure of the data and the d reduce the ability to detect 'molecular endotypes' within disease groups

1 INTRODUCTION

2

3 greatest unmet clinical needs of all musculoskeletal conditions^[1, 2], now recognised by the FDA as a

"serious disease"^[3, 4]. OA is a disease of the synovial joints manifesting as localised, low-grade

inflammation greatest unmet clinical needs of all musculoskeletal conditions^[1, 2], now recognised by the FDA as a

f serious disease^{7[3, 4]}. OA is a disease of the synovial joints manifesting as localised, low-grade

inflammation Inflammation of the synovium, cartilage damage and subchondral bone remodeling^[5], which lead to
pain, stiffness and loss of function^[6,7]. Despite growing clinical demand and best efforts in pre-
clinical models and 5 'serious disease'^[3, 4] inflammation of the synovium, cartilage damage and subchondral bone remodeling^[5], which lead to
pain, stiffness and loss of function^[6,7]. Despite growing clinical demand and best efforts in pre-
clinical models and pain, stiffness and loss of function^{16, 7}. Despite growing clinical demand and best efforts in preclinical models and translational studies to understand the underlying pathogenesis, target discovery
and drug developmen 8 clinical models and translational studies to understand the underlying pathogenesis, target discovery
and drug development for knee OA in humans have been slow^[8]. Results from randomised clinical
trials of putative dise and drug development for knee OA in humans have been slow^[8]. Results from randomised clinical

10. Trials of putative disease-modifying osteoarthritis drugs (DMOADs) have been largely disappointing^[9,10]

1^{10]} with

12

trials of putative disease-modifying osteoarthritis drugs (DMOADs) have been largely disappointing^{19,}
11 ^{10]} with a few treatments showing modest effects on cartilage preservation^[11, 12].
12 OA might not be a singl 10] with a few treatments showing modest effects on cartilage preservation^[11, 12].

12. OA might not be a single disease^[13, 14] but rather a group of diseases with

14. presentation but driven by distinct molecular OA might not be a single disease^[13, 14] but rather a group of diseases with a similar clinical
14 presentation but driven by distinct molecular pathways known as 'endotypes'. These might
15 determine the course of dise 14 determine the course of disease and in some cases predict response to treatment. It is presumed
that molecular endotypes might relate to discernible patient characteristics and may help to explain
the heterogeneity of OA ' 15 that molecular endotypes might relate to discernible patient characteristics and may help to explain
the heterogeneity of OA 'clinical phenotypes'^[15, 16]. Many cellular processes have been proposed as
critical drivers 16 the heterogeneity of OA 'clinical phenotypes'^[15, 16]. Many cellular processes have been proposed as
critical drivers in OA pathogenesis such as immune-mediated inflammation^[17], mechanically-
mediated inflammation (' the heterogeneity of OA 'clinical phenotypes'^{(15, 16}). Many cellular processes have been proposed as

18. critical drivers in OA pathogenesis such as immune-mediated inflammation^[17], mechanically-

19. mediated infla critical drivers in OA pathogenesis such as immune-mediated inflammation^[17], mechanically-

19 mediated inflammation ('mechanoflammation')^[18], low/failed tissue repair^[19, 20] and cellular

20 senescence^[21]. Th mediated inflammation ('mechanoflammation')^[18], low/failed tissue repair^{[19, 20}] and cellular senescence^[21]. These in turn may relate to a broad range of aetiological factors that are associated with OA^[22-26]. senescence^[21]. These in turn may relate to a broad range of aetiological factors that are associated

21. with OA^[22-26]. Efforts have been made to classify subgroups of people with OA based on

22. epidemiological f with OA^[22-26]. Efforts have been made to classify subgroups of people with OA based on
epidemiological factors^[27], with several clinically defined phenotypes now suggested in the
literature^[9, 28-30]. A recent sys epidemiological factors^[27], with several clinically defined phenotypes now suggested in the

literature^[9, 28-30]. A recent systematic review of 24 studies reported that up to 84% of people with

OA could be assigned literature^[9, 28-30]. A recent systematic review of 24 studies reported that up to 84% of people with
OA could be assigned to at least one of six phenotypes^[28, 31]. These clinical phenotypes are, however,
not mutuall 25 not mutually exclusive, and are poor systematic classifiers because they are a mixture of overlapping
26 demographic, clinical, radiographic, aetiological and systemic features. They currently have limited
27 clinical 25 not mutually exclusive, and are poor systematic classifier more in the a minimal of overlapping
demographic, clinical, radiographic, aetiological and systemic features. They currently have limited
clinical applicability^{[2} 26 clinical applicability^[29] and there is a paucity of data relating them to distinct molecular pathways or
to clinical outcomes in OA^[32].
Whilst there has been a plethora of studies of candidate molecules trying to id

29

Whilst there has been a plethora of studies of candidate molecules trying to identify diagnostic or
prognostic biomarkers of OA, relatively few have used hypothesis-free approaches in large numbers 28 to clinical outcomes in OA^[32].
29. Whilst there has been a pletl
31. prognostic biomarkers of OA,
32. of human biological sample 30 prognostic biomarkers of OA, relatively few have used hypothesis-free approaches in large numbers
of human biological samples to identify molecular endotypes^[28, 33, 34]. Such collaborations are
required to help move bio 31 prognostic biomarkers of O. identify molecular endotypes^[28, 33, 34]. Such collaborations are
required to help move biomarker discovery forward^[35]. Two broad matrices have been studied:
blood (plasma or serum), which of human biological samples to identify molecular endotypes^[28, 33, 34]. Such collaborations are
33 required to help move biomarker discovery forward^[35]. Two broad matrices have been studied:
34 blood (plasma or seru required to help move biomarker discovery forward^[35]. Two broad matrices have been studied:
34. blood (plasma or serum), which has the advantage of accessibility, and synovial fluid (SF), acquired
35. by joint aspirati 34 by joint aspiration. SF has several advantages over blood for exploring molecular mechanisms. 35 by joint aspiration. See has several advantages over blood for exploring molecular mechanisms.
S

36 Firstly, it has adjacency to joint tissues, and may reflect activities in synovium, bone as well as cartilage^[36-38]. Secondly, concentrations of analytes within the SF provide an indication of biological activity and t cartilage^[36-38]. Secondly, concentrations of analytes within the SF provide an indication of biological
activity and target tissue activation^[39, 40]. Thirdly, the SF from a given joint is less confounded by
disease activity and target tissue activation^[39, 40]. Thirdly, the SF from a given joint is less confounded by disease at other sites than is, for example, blood. Finally, a number of analytes that are highly regulated in the 39

41

The <u>S</u>ynovial fluid <u>T</u>o detect molecular <u>E</u>ndoty<u>p</u>es by Unbiased Proteomics in OA (STEpUP OA)
Consortium was set up to address a primary objective: to determine whether there are detectable distinct molecular endotypes in knee OA, through a hypothesis-free, unsupervised proteomic 42 The Synon must consortium was set up to address a primary objective: to determine whether there are detectable
distinct molecular endotypes in knee OA, through a hypothesis-free, unsupervised proteomic
analysis applying S 43 distinct molecular endotypes in knee OA, through a hypothesis-free, unsupervised proteomic
analysis applying SomaLogic array technology^[43] of SF from a large number of participants with, or at
increased risk of, knee OA 44 analysis applying SomaLogic array technology^[43] of SF from a large number of participants with, or at
increased risk of, knee OA. SomaScan, an aptamer-based proteomics technology, offers the ability to
measure large nu analysis applying SomaLogic array technology^[43] of SF from a large number of participants with, or at
46 increased risk of, knee OA. SomaScan, an aptamer-based proteomics technology, offers the ability to
47 measure lar 46 increasure large numbers of protein analytes from a small volume of biological fluid. However,
detailed methodology is lacking for quality control (QC) and data analysis pipelines specifically
tailored to SF.
SF presents a 47 measured methodology is lacking for quality control (QC) and data analysis pipelines specifically
tailored to SF.
SF presents analysis challenges due to its complex matrix which is rich in hyaluronan making the fluid
visco 48 49

tailored to SF.
SF presents analysis challenges due to its complex matrix which is rich in hyaluronan making the fluid
viscous, variability in joint effusion volume between and within patients, and potential
contamination SF presents an
Viscous, varia
contamination
treatment of t 50 viscous, variability in joint effusion volume between and within patients, and potential
contamination with blood at time of aspiration. To combat some of these challenges, hyaluronidase
treatment of the fluid post aspira 51 contamination with blood at time of aspiration. To combat some of these challenges, hyaluronidase
treatment of the fluid post aspiration or lavage of the joint prior to aspiration have been utilised^[42,144]. 52 treatment of the fluid post aspiration or lavage of the joint prior to aspiration have been utilised^[42,144].

In this study we describe the processing and analysis of SF, and the optimisation of a standardised 54^{44}

55

treatment of the fluid post aspiration or lavage of the joint prior to aspiration have been utilised^{[42,}
54 44].
55 In this study we describe the processing and analysis of SF, and the optimisation of a standardised t
.
.
. 56 In this study we describe the processing and analysis of SF, and the optimisation of a standardised
quality control (QC) and analysis pipeline for these data. We evaluate performance of SF on the
SomaLogic platform at scal 57 Somalogic platform at scale for the first time and identify important technical confounders requiring
adjustment prior to downstream analysis. Prespecified potential confounding factors included those
relating to sample pr 58 Somalogic plane in a countrier and interest time and identify important confounding factors included those
adjustment prior to downstream analysis. Prespecified potential confounding factors included those
relating to samp 59 relating to sample processing or to the sample itself, such as its age, number of freeze-thaws, visible
blood staining and sample volume. These investigations were used to inform STEpUP OA's primary
data analysis plan (htt 60 blood staining and sample volume. These investigations were used to inform STEpUP OA's primary
data analysis plan (https://www.kennedy.ox.ac.uk/oacentre/stepup-oa/stepup-oa) and make our
work replicable by others. 61 data analysis plan (https://www.kennedy.ox.ac.uk/oacentre/stepup-oa/stepup-oa) and make our
work replicable by others. 62 work replicable by others.
When the plan (https://www.kennedy.org/web/oacentre/stepup-oalstepup-oalstepup-oalstepup-oalstepup-oalstepup-o
And make our control of the material and make our control of the material of the mat 63 work replicable by others.
The by others is the big of the big distribution of
The big distribution of the big distribution of

- 64
- 65

66 METHODS

67 Methods. Working groups oversaw key activities (Figure S1). Six participating sites with 17
participant collections (henceforth referred to as 'cohorts') including those with either knee OA or
acute knee joint injury provi 68 Methods. Methods. Working groups oversaw they actually paper stay. The paralyting sites with $\frac{1}{2}$
participant collections (henceforth referred to as 'cohorts') including those with either knee OA or
acute knee joint i 69 acute knee joint injury provided associated SF samples. Each had ethical approval (Table S1). In addition, the University of Oxford Medical Sciences Central University Research Ethics Committee (CUREC) granted ethical appr 70 addition, the University of Oxford Medical Sciences Central University Research Ethics Committee
(CUREC) granted ethical approval for the processing, storage and use of samples and linked data for
this project on 1st Nov 71 addition, the University of University of Orfinsor Orfinsor Central Sciences Central University Central University
(CUREC) granted ethical approval for the processing, storage and use of samples and linked data for
this pr 72 (CUREC) gradies on 1st November 2019 (R67029/RE001).

Participant eligibility criteria

All but one cohort had existing associated stored participant SF samples. Inclusion criteria were: i)

74

75 Participant eligibility criteria

this project on 1st November 2019 (R67029/RE001).
74
Participant eligibility criteria
76 All but one cohort had existing associated stored p
77 evidence of a confirmed diagnosis of knee OA, or h 76 evidence of a confirmed diagnosis of knee OA, or history of recent knee injury, ii) associated basic
clinical information including (as a minimum) age at sampling, sex and indication of OA disease
status, iii) a minimum vo 77 clinical information including (as a minimum) age at sampling, sex and indication of OA disease
status, iii) a minimum volume of SF (90 µl, ideally 200 µl) and iv) SF had been centrifuged between
1800-3000g, prior to supe 78 status, iii) a minimum volume of SF (90 μ l, ideally 200 μ l) and iv) SF had been centrifuged between
1800-3000g, prior to supernatant storage at -80°C. Exclusion criteria were: i) additional forms of
arthritis e.g. g 79 $1800-3000g$, prior to supernatant storage at -80° C. Exclusion criteria were: i) additional forms of arthritis e.g. gout, rheumatoid arthritis, psoriatic arthritis, as determined by host investigator; ii) confounding 1800-3000g, prior to supernatant storage at -80°C. Exclusion criteria were: i) additional forms of
181 arthritis e.g. gout, rheumatoid arthritis, psoriatic arthritis, as determined by host investigator; ii)
182 confounding 81 arthritis e.g. gout, including medical conditions e.g. concurrent infection, cancer; iii) confounding treatments e.g.
index knee surgery in the preceding 6 months, index knee steroid injection in preceding 3 months;
iv) ch 82 confolex knee surgery in the preceding 6 months, index knee steroid injection in preceding 3 months;
iv) chemotherapy and; v) significant deviation in storage procedure (e.g. freezer drop-out defined by
host investigator). 83 iv) chemotherapy and; v) significant deviation in storage procedure (e.g. freezer drop-out defined by
host investigator). 84 inductions in the motion of the motion in storage processing and Somalogic assay

Sample processing and Somalogic assay

Consortium samples: 1746 SF samples were elig 85

86

87 Sample processing and SomaLogic assay

host investigator).
Sample processing
Consortium sampl
participant ID num 88 participant ID number (PIN) and related unique sample identification number (SIN) were generated
for each participant and their associated sample(s). Sample processing was performed in Oxford in
four tranches over a 24-mon 89 for each participant and their associated sample(s). Sample processing was performed in Oxford in
four tranches over a 24-month period. For analysis by SomaLogic, SF enzymatic digestion, using
hyaluronidase, was carried ou 90 four tranches over a 24-month period. For analysis by SomaLogic, SF enzymatic digestion, using
hyaluronidase, was carried out (Supplementary methods). Briefly, sufficient bovine testicular
hyaluronidase (4mg/ml; Sigma-Aldr 91 four tranches over a 24-monthload in the state of the statements of the state of the state of the state of the entire project was reconstituted as a single batch
from a single lot number and frozen in aliquots until use. F 92 hyaluronidase (4mg/ml; Sigma-Aldrich) for the entire project was reconstituted as a single batch
from a single lot number and frozen in aliquots until use. For each tranche, batch processing was
performed over consecutive 93 from a single lot number and frozen in aliquots until use. For each tranche, batch processing was
performed over consecutive working days, i.e. over as short a time as possible. Briefly, a batch of SFs
was thawed, centrifu 94 performed over consecutive working days, i.e. over as short a time as possible. Briefly, a batch of SFs
was thawed, centrifuged at 3000g at 20°C for 25 minutes and 175 µl of SF supernatant diluted 1:2
with the same volume 95 was thawed, centrifuged at 3000g at 20°C for 25 minutes and 175 µl of SF supernatant diluted 1:2 with the same volume of hyaluronidase solution and agitated at room temperature for 1 hour, followed by further centrifugati 96 with the same volume of hyaluronidase solution and agitated at room temperature for 1 hour, followed by further centrifugation for 5 minutes^{$[42]$}. Supernatants were aliquoted and stored at -80°C 97 Followed by further centrifugation for 5 minutes^[42]. Supernatants were aliquoted and stored at -80°C
 $\frac{1}{7}$ followed by further centrifugation for 5 minutes^[42]. Supernatants were aliquoted and stored at -80°C $\,$

99 100

101

tranche).
Consortium controls/QC samples: Equal volumes of SF samples from 6 participants per group were
used to generate single batches of hyaluronidase-treated 'pooled samples' for each of OA and knee ر
Consortiu
used to g
injury at t 102 used to generate single batches of hyaluronidase-treated 'pooled samples' for each of OA and knee
injury at the start of project. Subaliquots of these then acted as internal QC controls, being run on
each SomaLogic plate, 103 used to generate single batches single batches of these then acted as internal QC controls, being run on
each SomaLogic plate, enabling calculation of intra-assay and inter-assay coefficients of variation
(CVs), as well as 104 each SomaLogic plate, enabling calculation of intra-assay and inter-assay coefficients of variation
(CVs), as well as assessing effects of freeze thaw (a multiple freeze-thawed aliquot), frozen storage
of hyaluronidase (an 105 extingly) (CVs), as well as assessing effects of freeze thaw (a multiple freeze-thawed aliquot), frozen storage
of hyaluronidase (an untreated aliquot freshly treated with frozen hyaluronidase during processing
of each tra 106 (CVS) of hyaluronidase (an untreated aliquot freshly treated with frozen hyaluronidase during processing
of each tranche) and centrifugation (an additional unspun pooled sample, from 6 unspun OA SF
samples). A further 18 s 107 of each tranche) and centrifugation (an additional unspun pooled sample, from 6 unspun OA SF
samples). A further 18 samples (split at the time of collection, with the paired aliquot remaining
'unspun') were included to fur 108 of each tranchein and any present empericularity of empericies samples). A further 18 samples (split at the time of collection, with the paired aliquot remaining 'unspun') were included to further examine the effects of ce 109 Sunspun') were included to further examine the effects of centrifugation. 42 other 'comparator'
samples were included (disease-free controls from non-painful knees or from normal joints at
amputation/post-mortem; samples f 110 samples were included (disease-free controls from non-painful knees or from normal joints at
amputation/post-mortem; samples from individuals with definite inflammatory arthritis). Three
samples from three separate partici 111 amputation/post-mortem; samples from individuals with definite inflammatory arthritis). Three
samples from three separate participants were re-processed under 3 different temperature
conditions and re-analysed to examine t 112 samples from three separate participants were re-processed under 3 different temperature
conditions and re-analysed to examine the effects of laboratory re-processing. A subgroup of the
freshly collected samples were proce 113 conditions and re-analysed to examine the effects of laboratory re-processing. A subgroup of the freshly collected samples were processed specifically to test generalizability to OA SF which had not been centrifuged ('unsp 114 conditions and re-analysed to entimate the effects of laboratory re-processing. A subgroup of the
freshly collected samples were processed specifically to test generalizability to OA SF which had not
been centrifuged ('uns 115 free in the samples were subsequently included in the
replication analysis.
Samples were assayed on the SomaLogic SomaScan Discovery Plex V4.1 by SomaLogic, in Boulder, 116

118

replication analysis.
Samples were assayed on the SomaLogic SomaScan Discovery Plex V4.1 by SomaLogic, in Boulder,
US. All samples from all 4 tranches were processed as a single batch on twenty-two sequential 96-117 replication analysis.
118
119 Samples were assay
120 US. All samples fron
121 well plates in Januar 119 well plates in January 2022. All samples were randomised within and between plates whilst ensuring
appropriate controls on each plate. Each plate included 83 participant SF single samples; one pooled
OA sample; one pooled 120 US. All samples from all 4 tranches were randomised within and between plates whilst ensuring
appropriate controls on each plate. Each plate included 83 participant SF single samples; one pooled
OA sample; one pooled knee 121 appropriate controls on each plate. Each plate included 83 participant SF single samples; one pooled
OA sample; one pooled knee injury sample; five plasma calibrator samples; three plasma QC samples
and three blanks per pl 122 appropriate controls on each plate control plate intractors paramplies to englessing QC samples
and three blanks per plate. The SomaScan platform quantified 7,596 synthetic DNA SOMAmers (for
7289 human targets) (Slow Off 123 and three blanks per plate. The SomaScan platform quantified 7,596 synthetic DNA SOMAmers (for
7289 human targets) (Slow Off-rate Modified Aptamers^[45, 46]) that bound to 6596 unique human
proteins. The generated SomaSc 124 7289 human targets) (Slow Off-rate Modified Aptamers^[45, 46]) that bound to 6596 unique human
proteins. The generated SomaScan protein quantification was securely transferred from SomaLogic
to Oxford as .adat files. 7289 human targets) (Slow Off-rate Modified Aptamers^[45, 46]) that bound to 6596 unique human
126 proteins. The generated SomaScan protein quantification was securely transferred from SomaLogic
127 to Oxford as adat file 126 127

128

proteins and generated Somalisms protein quantification was securely transferred from Somalogic
to Oxford as .adat files.
Oxford and at SomaLogic, included: sample blood staining (by visual staining defined by host Additional sample met:
Oxford and at SomaLc
investigator at time of 129 Oxford and at SomaLogic, included: sample blood staining (by visual staining defined by host
investigator at time of collection); initial centrifugation of the sample; number of previous freeze
thaws; the date of laborator 130 Investigator at time of collection); initial centrifugation of the sample; number of previous freeze
thaws; the date of laboratory processing; batch and order of processing; the plate and position of
8 131 thaws; the date of laboratory processing; batch and order of processing; the plate and position of $\frac{8}{3}$ 132 that γ is that contributing; batch and order or

8

133 the sample. These sample metadata were defined as technical confounders in our QC pipeline (Table
S2).
Clinical data
Pseudonymised associated participant clinical data were transferred from participating sites to

- 134
- 135
- 136 Clinical data

Oxford, linked to their consortium PIN, mapped to variables where necessary and uploaded to a 137 Oxford, linked to their consortium PIN, mapped to variables where necessary and uploaded to a
REDCap database (Research Electronic Data Capture, Vanderbilt University, US)^[47], hosted by the
University of Oxford. Data in 138 REDCap database (Research Electronic Data Capture, Vanderbilt University, US)^[47], hosted by the University of Oxford. Data integrity and completeness were ensured using a data dictionary, data entry constraints and a co REDCap database (Research Electronic Data Capture, Vanderbilt University, US)^[47], hosted by the

140 University of Oxford. Data integrity and completeness were ensured using a data dictionary, data

141 entry constrain 140 University of Oxford. Data integrity and completeness were ensured using a data dictionary, data
entry constraints and a combination of automated, systematic and random checks by two of the
study team.
A consortium working 141 142

143

entry consortium working group oversaw all aspects of data management including definition of
A consortium working group oversaw all aspects of data management including definition of
variables and associated data dictiona study team.
A consortium
variables and
Informed by 144 Variables and associated data dictionary, data harmonisation and design of the database (Figure S1).
Informed by their relative clinical importance, by data availability and by iterative review, a core
clinical dataset (a 145 variables and associated data distinctionary) variables and availability and by iterative review, a core clinical dataset (a subset of the data dictionary) was defined: the first phenotype release "Pheno 1" (demographic da 146 Inical dataset (a subset of the data dictionary) was defined: the first phenotype release "Pheno 1"
(demographic data and harmonised measures of radiographic disease severity) and the second
release "Pheno 2" (dichotomous 147 (demographic data and harmonised measures of radiographic disease severity) and the second
release "Pheno 2" (dichotomous and continuous harmonised patient-reported outcome measures
for knee pain^[48]). (Table S2 & Suppl 148 release "Pheno 2" (dichotomous and continuous harmonised patient-reported outcome measures
for knee pain^[48]). (Table S2 & Supplementary methods). 149

151

152 Data QC approach

Methods to develop QC and data analysis pipelines prior to the primary discovery analysis were prefor knee pain^[48]). (Table S2 & Supplementary methods).
151
Data QC approach
153 Methods to develop QC and data analysis pipelines prio
154 defined in the Quality Assurance plan (https://www.ke 153 confounders and filtering based on pre-defined quality thresholds for SOMAmers, proteins and 154 samples. The approach included pre-defined data exploration, though where issues were found, 155 oa). This QC pipeline aimed to validate methods for standardisation of the data, through a series of
normalisation steps (given that SF was a non-standard matrix on SomaScan), correction for technical
confounders and filte 156 nonfounders and filtering based on pre-defined quality thresholds for SOMAmers, proteins and
samples. The approach included pre-defined data exploration, though where issues were found,
these were iteratively investigated 157 samples. The approach included pre-defined data exploration, though where issues were found,
these were iteratively investigated and findings used to refine the QC pipeline. This approach was
informed by our prior publish 158 stamples. The approach included pre-defined and exploration, the again inter-defined in the reaming these were iteratively investigated and findings used to refine the QC pipeline. This approach was informed by our prior p 159 informed by our prior published work^[42], SomaLogic expertise, initial consortium pilot work on 435
samples previously assessed on an earlier version (4.0) of the SomaScan platform, and subsequent
QC work within this da informed by our prior published work^[42], SomaLogic expertise, initial consortium pilot work on 435
161 samples previously assessed on an earlier version (4.0) of the SomaScan platform, and subsequent
162 QC work within 161 162

163

The usual SomaScan analysis pipeline for plasma involves a series of standardisation procedures to
reduce nuissance variance, using plasma calibrator and plasma QC samples included on plates to The usual SomaScan analysis
The usual SomaScan analysis
reduce nuissance variance, 164 The usual Somalism analysis pipeline for plasma involves a series of standardisation plates to
reduce the effect of technical factors across samples and plates^[49]. This routine standardisation of
9 165 reduce the effect of technical factors across samples and plates^[49]. This routine standardisation of 9 reduce the effect of technical factors across samples and plates^[49]. This routine standardisation of 9
9

167 the SomaScan relative fluorescence units (RFU), adjusted by the protein's dilution factor used in the
SomaScan assay (the "dilution bin"), was applied in a stepwise way, using i) hybridisation control
normalisation (to rem 168 Somalisation (to remove well-to-well variation due to different rates of hybridisation between
SOMAmers and fluorescence probes using spiked-in control SOMAmers); ii) plate scaling using
plasma calibrators (to remove varia 169 normalisation (to remove probes using spiked-in control SOMAmers); ii) plate scaling using
plasma calibrators (to remove variation in overall intensity between plates); iii) median signal
normalisation (to decrease variati 170 plasma calibrators (to remove variation in overall intensity between plates); iii) median signal
normalisation (to decrease variation due to total fluorescence intensity between samples); and iv)
calibration (using plasma 171 plasma calibration (to decrease variation due to total fluorescence intensity between samples); and iv) calibration (using plasma calibrator samples of known concentration to rescale each protein and reduce assay differenc 172 calibration (using plasma calibrator samples of known concentration to rescale each protein and
reduce assay differences between runs). Each normalisation step was tested in a sequential manner.
After optimised standardisa 173 174

175

pre-specified continuous covariates, as described below. The batch correction method ComBat (in After optimised standardisation, the R package *limma* was used to adjust proteins for a number of
pre-specified continuous covariates, as described below. The batch correction method ComBat (in
sva R package) was applied 176 pre-specified continuous covariates, as described below. The batch correction method ComBat (in sva R package) was applied^[50] to adjust the mean and variance of each protein for batch effects in datasets where the batc 177 sva R package) was applied^[50] to adjust the mean and variance of each protein for batch effects in
datasets where the batch covariate, such as plate, is known^[44] (again, as described below).
Based on our initial QC a sva R package) was applied^[50] to adjust the mean and variance of each protein for batch effects in
179 datasets where the batch covariate, such as plate, is known^[44] (again, as described below).
181 Based on our ini

180

datasets where the batch covariate, such as plate, is known^[44] (again, as described below).

180

Based on our initial QC assessments, to quantify and adjust for differences in the contr

182 intracellular proteins to 181 intracellular proteins to the proteome, we defined an Intracellular Protein Score (IPS) for each
sample *i*, as a weighted sum of protein concentrations using the equation 182 sample *i*, as a weighted sum of protein concentrations using the equation
 $IPS_i = \sum_p d_p C_{ip}$ 183

184

$$
IPS_i = \sum_p d_p C_{ip}
$$

where d_p is the Cohen's d for the difference in concentration for protein p between paired spun and $\frac{1}{2}$ 185 unspun samples, and C_{ip} is the log concentration of protein p in sample i.
Checks of assay performance and biological validity were carried out by measuring repeatability 186

187

is the Cohen's d for the difference in concentration for protein p between paired spun and
imples, and C_{ip} is the log concentration of protein p in sample i .
i assay performance and biological validity were carri unspun samples, and c_{ip} is the log concentration of protein p in sample t .
Checks of assay performance and biological validity were carried out k
using the pooled samples on each plate, use of metadata for prespeci 188 Checks of metals of analytical validity in the called streamly interesting repeatancy
using the pooled samples on each plate, use of metadata for prespecified technical confounders, and
comparison with previously generated 189 comparison with previously generated quantitative immunoassay data (R&D or Meso Scale
Discovery, available for 60 OA and injury SF samples (without hyaluronidase treatment) for 9
overlapping proteins (Table S3). 190 Discovery, available for 60 OA and injury SF samples (without hyaluronidase treatment) for 9 overlapping proteins (Table S3).
Statistics and Analysis 191 overlapping proteins (Table S3).
Discovery, and analysis
Principal Components Analysis (PCA) was used to visualize proteome-wide patterns of variation in 192

193

194 Statistics and Analysis

overlapping
Statistics and Analysis
Principal Components Analysis
the data, with further visual 195 Principal Components Analysis (PCA) with distance protection (PCS) with Uniform Manifold
Approximation and Projection (UMAP) 2-dimensional plots (UMAP applied to the set of top PCs that
explained >80% of total variation). 196 Approximation and Projection (UMAP) 2-dimensional plots (UMAP applied to the set of top PCs that
explained >80% of total variation). Various other bioinformatic, descriptive and statistical techniques
were employed to test 197 explained >80% of total variation). Various other bioinformatic, descriptive and statistical techniques 198 were employed to test the quality of the data. We checked:
10 199 were employed to test the quality of the data. We checked:

231 limits of detection respectively, the sample was removed.

248 RESULTS

249 Of 1746 unique participant samples included, tranches 1&2 were designated the Discovery analysis
dataset (comprising 1045 samples), and tranches 3&4 the Replication analysis dataset (701 samples).
Selection of Each Normali 250

251

252 Selection of Each Normalisation Procedure

253

dataset (comprising 2012 samples), and transhes 3.4 the Replication analysis dataset (702 samples).
Selection of Each Normalisation Procedure
These had been previously optimised by SomaLogic for plasma samples. We set out 254

- 255
- 256

These had been previously optimised by SomaLogic for plasma samples. We set out to test how well
these procedures performed in all 1746 SF samples with 7596 SOMAmer features.
We measured the impact of technical variation i These procedures performed in all 1746 SF samples with 7596 SOMAmer features.
We measured the impact of technical variation in each normalisation step (see methods) on assay
performance in a sequential manner, firstly by m these performance in a sequential manner, firstly by measuring effects on the mean %C
performance in a sequential manner, firstly by measuring effects on the mean %C
across all proteins for the pooled sample replicates acr 257 performance in a sequential manner, firstly by measuring effects on the mean %CV and the mean R^2
across all proteins for the pooled sample replicates across all plates (Figure 1A&B). Comparing each
to the raw RFU data, performance in a sequential manner, firstly by measuring effects on the mean %CV and the mean R²
259 across all proteins for the pooled sample replicates across all plates (Figure 1A&B). Comparing each
260 to the raw RF 259 to the raw RFU data, %CVs ranged from 11.65% to 16.49% for pooled OA samples (n=22) and 10.56%
to 16.63% for pooled injury samples (n=22). Mean R² ranged from 77.70% to 88.98% and 82.59% to
89.10% for pooled OA and inju 260 to 16.63% for pooled injury samples (n=22). Mean R^2 ranged from 77.70% to 88.98% and 82.59% to 89.10% for pooled OA and injury samples respectively, suggesting a high level of repeatability. A decreasing trend in mean to 16.63% for pooled injury samples (n=22). Mean R² ranged from 77.70% to 88.98% and 82.59% to
262 89.10% for pooled OA and injury samples respectively, suggesting a high level of repeatability. A
263 decreasing trend i 262 decreasing trend in mean %CVs suggested that the routine normalisation steps improved measure
repeatability with the exception of median normalisation (Figure 1A&B). Removing median
normalisation from the standardisation 263 repeatability with the exception of median normalisation (Figure 1A&B). Removing median
normalisation from the standardisation procedure resulted in a mean %CV of 13.6% and a mean R^2
of 88.98% for pooled OA samples and 264 normalisation from the standardisation procedure resulted in a mean %CV of 13.6% and a mean R²
of 88.98% for pooled OA samples and %CV of 14.34% and a mean R² of 89.1% for pooled injury
samples (Figure 1A&B). 265 normalisation from the standardisation procedure resulted in a mean %CV of 13.6% and a mean R²
266 of 88.98% for pooled OA samples and %CV of 14.34% and a mean R² of 89.1% for pooled injury
267 samples (Figure 1A& 267

268

266 of 88.98% for pooled OA samples and %CV of 14.34% and a mean R² of 89.1% for pooled injury
267 samples (Figure 1A&B).
268 Correlation of the SomaScan assay data with nine selected analytes measured in the same SF sam samples (Figure 2012).
Correlation of the Soma
by immunoassay was ge
steps, we saw a similar 269 EXTERT THE SOMETHE EVAY THE METHEM AND THE SOLUTE AND JOC METHEM THE STAMPLE CHAPTE
by immunoassay was generally high for most analytes (Figure 1C&D). However, upon normalisation
steps, we saw a similar effect, with median 270 by immunosity integration, inguitar interally the propertion protection, specificant steps, we saw a similar effect, with median signal normalisation reducing the correlation with these validation measurements, particularl 271 steps, we shall a similar effect, with meaning gian normalisation controlling the correlation measurements, particularly in the injury samples (Figure 1D). Based on these combined
data, we chose to use SomaLogic's existing 272 data, we chose to use SomaLogic's existing standardisation procedures, though omitting median
normalisation from our SF standardisation pipeline (i.e. employing hybridisation normalisation, plate
scaling, and plate calibra 273 normalisation from our SF standardisation pipeline (i.e. employing hybridisation normalisation, plate
scaling, and plate calibration using SomaLogic's plasma calibrators). 274 normalisation from our SF standardisation for the standardisation and correction of confounding factors

Identification and correction of confounding factors

After conducting standardisation, principal component (PC) anal 275

276

277 Identification and correction of confounding factors

stand, and plate calibration and correction of confounding factors
After conducting standardisation, principal component (PC) an
component (PC1) that explained 48% of variation in the data (Figur 278 Component (PC1) that explained 48% of variation in the data (Figure 2A). This principal component was positively correlated with almost all proteins measured, with a median correlation coefficient of 0.70, with the highes 279 component (PCL) that explained 1888 of variation in the data (Figure 2A). This principal component
was positively correlated with almost all proteins measured, with a median correlation coefficient of
0.70, with the highes 280 0.70, with the highest correlations seen with low abundance proteins (Figure 2B). We were able to 281 $\mathcal{O}(\mathcal{O}^{\text{max}})$ with the highest correlations seen with low abundance proteins (Figure 2B). We were able to

282 rule out a total protein effect, due to a low correlation (-0.039) with standard high-abundance
markers such as albumin concentration. Examining the proteins that drove this signal, we found that
lower protein abundance wa 283 marker protein abundance was the strongest independent predictor of correlation (Table S5) with PC1
(p< 2.23e-308), with the next most significant predictors being whether proteins were predicted not
to be secreted (p=3.98 284 (p <2.23e-308), with the next most significant predictors being whether proteins were predicted not
to be secreted (p =3.98e-10) and proteins that were identified as nuclear and not secreted (p =1.64e-
9). This led to 285 (p=3.98e-10) and proteins that were identified as nuclear and not secreted (p=1.64e-
9). This led to the hypothesis that PC1 was capturing an effect of intracellular proteins, perhaps
reflecting cell turnover or due to the 286 t_{source} (noming same parent style ω) and had been spin mediator and entire span of left anspair 287 reflecting cell turnover or due to the presence of microvesicles. A strong intracellular signal was
confirmed by showing that PC1 was consistently reduced in spun samples when comparing paired SF
samples (from the same par 288 confirmed by showing that PC1 was consistently reduced in spun samples when comparing paired SF
samples (from the same parent SF, n =18) that had been split into two and either spun or left unspun
immediately after joint a 289 confirmed by samples (from the same parent SF, n =18) that had been split into two and either spun or left unspun
immediately after joint aspiration (Figure 2C).
To quantify the contribution of intracellular proteins, we d 290 291

292

immediately after joint aspiration (Figure 2C).
To quantify the contribution of intracellular proteins, we derived an Intracellular Protein Score (IPS)
as the weighted sum of relative protein concentrations. For weights, w Immediately after joint approach (Figure 20).
To quantify the contribution of intracellular p
as the weighted sum of relative protein conce
the 18 paired spun and unspun samples. This 293 To as the weighted sum of relative protein concentrations. For weights, we calculated a Cohen's d from
the 18 paired spun and unspun samples. This score correlated very highly with PC1 (Figure 2D). We
used this score in a 294 the 18 paired spun and unspun samples. This score correlated very highly with PC1 (Figure 2D). We
used this score in a linear regression model adjusting for the contribution of intracellular proteins,
which removed the cor 295 the 18 pairs of pairs of pairs of pairs in pairs of the contribution of intracellular proteins,
used this score in a linear regression model adjusting for the contribution of intracellular proteins,
which removed the corre 296 which removed the correlation between IPS and PC1 (Figure 2E), reduced the variance explained by
PC1 to 16% (Figure 2F), and removed the correlation of "non-secreted nuclear protein" with PC1
(Table S5). 297 which removed the correlation between IPS and ϵ (Figure 2E), reduced the constant of explained by PC1 to 16% (Figure 2F), and removed the correlation of "non-secreted nuclear protein" with PC1 (Table S5).
(Table S5). 298 299

300

PC1 (Table S5).
Phis intracellular contribution to the SF proteome did not correlate strongly with any of our pre-
This intracellular confounders. However, it explained a large proportion of variation in our data, (Table St₎.
This intract
defined term 301 μ miary dataset, applying instruction to each protein as part of our step of our plata miary is 302 which ran the risk of swamping more subtle protein signatures or molecular endotypes, if present.
We thus decided to include, in addition to the standardised data set without IPS adjustment, a co-
primary dataset, applying 303 We thus decided to include, in addition to the standardised data set without IPS adjustment, a coprimary dataset, applying IPS adjustment to each protein as part of our STEpUP OA Data Analysis
Plan (https://www.kennedy.ox. 304 305 306

307

We also found a strong 'bimodal' signal on PC2 of the data (Figure 3A&B) whereby a large number of primary dataset, applying instantional states protein as part of our STEPUP of STEPUP (mail, and
Plan (https://www.kennedy.ox.ac.uk/oacentre/stepup-oa/stepup-oa).
We also found a strong 'bimodal' signal on PC2 of the data Plan (https://www.ken.com
Plan (https://www.kennedy.org/stepup-of-stepup-of-stepup-of-stepup-of-stepup-of-stepup-of-stepup-of-stepup-of-
Plan (https://www.kennedy.org/stepup-of-stepup-of-stepup-of-stepup-of-stepup-of-stepu 308 SOMAmers (N=4030 at Benjamini–Hochberg (BH) adjusted p<0.05) were present at either very low
or very high relative signal in a given sample. Further investigation showed that PC2 was highly
correlated with the technical va 309 SOMAINETS (N=4030 at Benjamini–Hochberg (BH) adjusted p<0.05) were present at either very low
or very high relative signal in a given sample. Further investigation showed that PC2 was highly
correlated with the technical v 310 correlated with the technical variable 'laboratory processing batch' (p<2.2E-308). Investigation of exemplar proteins displaying this behaviour showed that the bimodal signal followed sample processing order, usually (but 311 exemplar proteins displaying this behaviour showed that the bimodal signal followed sample
processing order, usually (but not always) between laboratory processing batches (Figure 3C). The 312 exemplar processing order, usually (but not always) between laboratory processing batches (Figure 3C). The effect became stronger over time (Figure 3C). Re-analysing (at SomaLogic) previously laboratory processed (hyaluron 313 processed (hyaluronidase treated) samples gave the same result (data not shown). However, when
processed (hyaluronidase treated) samples gave the same result (data not shown). However, when
14 314 processed (hyaluronidase treated) samples gave the same result (data not shown). However, when 315 processed (hyaluronidase treated) samples gave the same result (data not shown). However, when

316 new aliquots of three sequential samples which had differing bimodal status were reprocessed by
the Oxford laboratory and re-analysed, all three reprocessed results had a shared bimodal status.
This indicated that this was 317 This indicated that this was due, in some way, to our laboratory sample processing (hyaluronidase
treatment) (Figure 3D). We hypothesised this might be due to sample temperature differences prior
to hyaluronidase treatment 318 The indicated that the this processed this might be due to sample temperature differences prior
to hyaluronidase treatment, but further experiments did not corroborate this (data not shown).
Neither was this thought to be 319 to hyaluronidase treatment, but further experiments did not corroborate this (data not shown).
Neither was this thought to be due to the stability of frozen hyaluronidase enzyme as the pooled OA
sample, freshly processed d 320 to hyaluronidate treatment, but further experiments did not correspond the not contribute the shown.
Neither was this thought to be due to the stability of frozen hyaluronidase enzyme as the pooled OA
sample, freshly proce 321 sample, freshly processed during each tranche with frozen stored hyaluronidase, showed little
variability over time (Figure S2).
We applied a Gaussian Mixture Model to PC2 to classify samples into high or low protein statu 322 323

324

saminability over time (Figure S2).
Sample, freshed a Gaussian Mixture Model to PC2 to classify samples into high or low protein status, showed a Gaussian Mixture Model to PC2 to classify samples into high or low protein s variable of the constant Weal applied a Gaussian Mixture
Interflecting their bimodal signal (F
UMAP (Figure 3E&F). To attemp 325 reflecting their bimodal signal (Figure 3E), which produced visually plausible assignments on PCA and
UMAP (Figure 3E&F). To attempt to reduce this undesired variance, we carried out batch correction
by samples' PC2 bimoda 326 UMAP (Figure 3E&F). To attempt to reduce this undesired variance, we carried out batch correction
by samples' PC2 bimodal signal status using the ComBat method ^[50]. This correction reduced the
impact of the bimodal sign 327 by samples' PC2 bimodal signal status using the ComBat method ^[50]. This correction reduced the
impact of the bimodal signal considerably (Figure 3G&H) and was adopted into our QC pipeline.
We also discovered a significa 329

330

by samples' PC2 bimodal signal status using the ComBat method ^[50]. This correction reduced the
329. Impact of the bimodal signal considerably (Figure 3G&H) and was adopted into our QC pipeline.
330. We also discovered a impact of the bimodal significant influence of plate on a number of proteins (n=1927) at BH adju
p<0.05). Our samples were randomised to plate, so this was unlikely to cause significant confour
in downstream analyses, but 331 We also discovered a significant influence of plate on a number of proteins (n=1927) at BH adjusted
p<0.05). Our samples were randomised to plate, so this was unlikely to cause significant confounding
in downstream analyse 332 in downstream analyses, but to reduce technical variation we also applied batch correction for plate
by ComBat at the same time as correcting for the bimodal signal.
We assessed the impact of these adjustments described ab 333 334

335

in dominate team analyses, but to reduce technical variation of any operation for the plate of by ComBat at the same time as correcting for the bimodal signal.
We assessed the impact of these adjustments described above us by ComBat at the same of these adjustments described above to data. While the IPS-adjustment reduced the dominance of PC1, if
correlation coefficients between SomaScan and prior immunoa 336 data. While the IPS-adjustment reduced the dominance of PC1, it also had a negative impact on the
correlation coefficients between SomaScan and prior immunoassay results of the select analytes
(Figure 4). This was particul 337 data. United the IPS-adjustment reduced the dominance of PC1, it also had a negative impact on the correlation coefficients between SomaScan and prior immunoassay results of the select analytes (Figure 4). This was particu 338 (Figure 4). This was particularly evident in the injury group, where the correlation between the two measures for 4 out of 9 proteins (IL6, IL8, TGFß1, TIMP1) changed from strongly correlated to weakly or not correlated (F 339 measures for 4 out of 9 proteins (IL6, IL8, TGFB1, TIMP1) changed from strongly correlated to weakly
or not correlated (Figure 4B). Interestingly, some of the measured cytokines (which had been
selected because of their pu 340 or not correlated (Figure 4B). Interestingly, some of the measured cytokines (which had been
selected because of their putative disease relevance) such as MCP1, IL-8 and TGFß1, correlated with
the intracellular protein sco 341 selected because of their putative disease relevance) such as MCP1, IL-8 and TGFß1, correlated with
the intracellular protein score (Table S6). Batch correction for plate and bimodal signal status (as
part of our optimised 342 she intracellular protein score (Table S6). Batch correction for plate and bimodal signal status (as
part of our optimised standardisation) was seen to have minimal impact on immunoassay
agreement (Figure 4). 343 the intracement protein score (Table Sey, 2006) scores from the unit and bimodal signal state (as
part of our optimised standardisation) was seen to have minimal impact on immunoassay
agreement (Figure 4).
Description and 344 agreement (Figure 4).
Description and reduction of pre-defined technical confounding by protein filtering
In addition to identifying badly performing SOMAmers and samples for filtering according to assay 345

346

347 Description and reduction of pre-defined technical confounding by protein filtering

agreement (Figure 4).
Description and reduc
In addition to identify
performance (see met 348 performance (see methods), we also identified filters based on pre-defined technical confounders 349 performance, μ and the filters based on pre-defined technical conformation on 15

350

351

(Table S2).
Confounding technical factors were dealt with in different ways. Samples showed systematic biases
in signal intensity plate position (Table S7, 'Plate position'), but this was also deemed unlikely to
confound d 352 In signal intensity plate position (Table S7, 'Plate position'), but this was also deemed unlikely to confound downstream analyses because samples were randomised across and within plates, so its effect was not adjusted fo 353 in signal interval intervals are the confound downstream analyses because samples were randomised across and within plates, so its effect was not adjusted for. Blood staining (Table S7, 'Visual blood staining') and sample 354 effect was not adjusted for. Blood staining (Table S7, 'Visual blood staining') and sample volume
were both drivers of IPS, but we felt that both could contain biological signals of relevance, so they
were not adjusted dur 355 effect was not adjusted for the statements for the statement statements of the sample of the statement were not adjusted during QC but were considered covariates in the downstream analyses. Sample age (Table S7, 'Sample ag 356 were not adjusted during QC but were considered covariates in the downstream analyses. Sample age (Table S7, 'Sample age') could introduce technical variation, therefore significantly associated proteins were removed by fi 357 age (Table S7, 'Sample age') could introduce technical variation, therefore significantly associated
proteins were removed by filtering (Table S4). Freeze-thawing was also shown to be a potential
technical confounder (Tabl 358 age (Table S4). Freeze-thawing was also shown to be a potential
technical confounder (Table S7, 'Sample freeze thaw cycles'). This was investigated further.
For freeze-thawing, we had repeatedly freeze-thawed (five times p 359 360

361

proteins were removed by meaning (Table S4). These infining was investigated further.
technical confounder (Table S7, 'Sample freeze-thaw cycles'). This was investigated further.
For freeze-thawing, we had repeatedly freez For freeze-thawing, we had repeatedly freeze-thawed (five times per sample) one aliquo
the pooled OA and the pooled injury samples. This had an effect, particularly in the injury
However, the majority (77%) of proteins ret 362 For freeze-thawing, the had repeatedly fived-that control (five times per sample) the injury samples.
The pooled OA and the pooled injury samples. This had an effect, particularly in the injury samples.
However, the majori 363 the poole of the poole injury samples the had an effect, parameter, parameter, and provide the poole of the po
However, the majority (77%) of proteins retained a good %CV (<20%) even after five freeze-thaws
(Figure S2), su 364 (Figure S2), suggesting that such samples remained usable. Technical variation brought about by
freeze-thaw was nonetheless adjusted for by filtering out significantly associated proteins following
Bonferroni correction (T 365 freeze-thaw was nonetheless adjusted for by filtering out significantly associated proteins following 366 367

368

369 Assessment of centrifugation effect on protein measurements

Although most of the samples had been centrifuged prior to initial storage as per our eligibility Bonferroni contenting (Table S4).
Assessment of centrifugation effection (Table S4).
Criteria, 240 samples included in 370 criteria, 240 samples included in the replication analysis were unspun. In anticipation of this we
assessed further the impact of centrifugation on the 18 pairs of samples that had either been spun
or left unspun at time o 371 assessed further the impact of centrifugation on the 18 pairs of samples that had either been spun. 372 or left unspun at time of collection. We compared the SomaScan data to identify proteins that
changed upon centrifugation (Figure S3). The effect of centrifugation on the data depended on
whether the data were adjusted for 373 whether the data were adjusted for IPS. The unadjusted data showed that centrifugation status was
a major driver of variation across the paired samples, with a significant correlation with PC1 (Figure
S3A, paired t-test p= 374 whether the data were adjusted for IPS. The unadjusted data showed that centrifugation status was
a major driver of variation across the paired samples, with a significant correlation with PC1 (Figure
S3A, paired t-test p= 375 a major driver of variation across the paired samples, with a significant correlation with PC1 (Figure
S3A, paired t-test p=0.0066), but after adjusting for IPS, the top PCs were no longer driven by spun
status (Figure S3B 376 S3A, paired t-test p=0.0066), but after adjusting for IPS, the top PCs were no longer driven by spun
status (Figure S3B, paired t-test p=0.2089). Centrifugation impacted the concentration of a large
number of individual p 377 status (Figure S3B, paired t-test p=0.2089). Centrifugation impacted the concentration of a large
number of individual proteins in both IPS-unadjusted (n=5638, 74%, at BH adjusted p<0.05) and, to a
lesser extent, IPS-adju 378 status (Figure 3)

status (Figure S2B, pair of a large point of a lesser extent, IPS-adjusted data (n=3731, 49%, at BH adjusted p<0.05), although the majority of

proteins were significantly correlated between the paired 379 handler of individual proteins in both is analyzion (n=000), although the majority of
lesser extent, IPS-adjusted data (n=3731, 49%, at BH adjusted p<0.05), although the majority of
proteins were significantly correlated 380 proteins were significantly correlated between the paired spun and unspun samples (n=6402, 85% in
unadjusted data and n=4558, 60% in IPS adjusted data, Figure S3C&D respectively). 381 proteins were significantly correlated between the paircule pair and unsput samples (n=6402, 2014 in
unadjusted data and n=4558, 60% in IPS adjusted data, Figure S3C&D respectively).
16 382 unadjusted data and n=4558, 60% in IPS adjusted data, Figure S3C&D respectively.
The state of the st
The state of the state of the

383

384 We concluded that spun and unspun samples were comparable (in that they captured similar information), but that any analysis that included both types together would need to adjust for systematic shifts in abundance and the 385 systematic shifts in abundance and the small numbers of uncorrelated proteins. In our discovery and 386 replication analysis plans relating to our primary analysis, only spun samples are therefore 387 replicansidered, with unspun samples used for secondary sensitivity analyses.

Effect of blood staining on protein measurements

A subset of samples had information on blood staining, graded by visual inspection at the tim 388

389

390 Effect of blood staining on protein measurements

considered, with unspun samples used for secondary sensitivity analyses.
Effect of blood staining on protein measurements
A subset of samples had information on blood staining, graded by visua
joint aspiration, prior to ce 391 A spiration, prior to centrifugation. As shown in Table S7, the presence of blood measured in this
way was a significant driver of protein variation. It was also a potential biological driver as
haemarthrosis is common aft 392 way was a significant driver of protein variation. It was also a potential biological driver as
haemarthrosis is common after significant joint injury and is known to be pro-inflammatory and
associated with persisting knee 393 Matemarthrosis is common after significant joint injury and is known to be pro-inflammatory and
associated with persisting knee symptoms^[51-53]. Visual blood staining could reflect presence of either
intact or lysed red 394 associated with persisting knee symptoms^[51-53]. Visual blood staining could reflect presence of either associated with persisting knee symptoms^[51-53]. Visual blood staining could reflect presence of either

intact or lysed red blood cells. The analyte haemoglobin A (HBA) correlated reasonably well with

visual blood sta 396 visual blood staining grade prior to adjustment for IPS (Figure S4A), and less so after adjustment for 397 IPS (Figure S4B). The log concentration of HBA relative abundance level (without IPS adjustment) 398 IPS (Figure Section 1998).

IPS (Was subsequently used as a measure of blood content, as a covariate in downstream analyses.
 Validation of data quality after QC

Following application of filters, 1720 samples and 6290 S 399

400

401 Validation of data quality after QC

was subsequently as a meaning of the content, as a counter in domination and post-
Validation of data quality after QC
Following application of filters, 1720 samples and 6290 SOMAmers (features) remained. The
numbers of sa 402 numbers of samples and proteins filtered out are shown in Table S4. After filtering, median %CV of pooled OA and injury samples remained relatively unchanged at 11.25 and 12.42 respectively (Figure S5). An overview of the 403 numbers of samples and proteins interested out are shown in table strated intering, instant for the
pooled OA and injury samples remained relatively unchanged at 11.25 and 12.42 respectively (Figure
S5). An overview of the 404 poole.
S5). An overview of the end-to-end data processing and quality control pipeline, from raw data to
final filtered data, is shown in Figure 5.
The association of all these variables with the top 10 PCs of the standard 405 406

407

S5). The exercise of the end-to-end-to-end-to-end-to-end-to-end-to-end-to-end-to-end-to-end-to-end-to-end-to-e
S5). The association of all these variables with the top 10 PCs of the standardised, bimodal signal
corrected d final filters and, it shows the association of all these variables
corrected data after filtering is shown
filtered data are shown in Figure 6. IPS 408 The strongest associations in the IPS adjusted,
Filtered data are shown in Figure 6. IPS adjusted non-filtered, and non-IPS adjusted data are shown
in Figure S6.
In Figure S6. 409 corrected data are shown in Figure 6. IPS adjusted non-filtered, and non-IPS adjusted data are shown
in Figure S6.
Finally, we visualised the different diagnostic subgroups (OA, joint injury, inflammatory control, 410 411

412

filter of the different diagnostic subgroups (OA, joint injury, inflammatory control,
Finally, we visualised the different diagnostic subgroups (OA, joint injury, inflammatory control,
disease-free control) on UMAPs of the in Figure 23.
Finally, we v
disease-free
IPS adjustme 413 Finally, the control) on UMAPs of the standardised, corrected and filtered data, with and without
IPS adjustment (Figure 7A&B respectively). Both datasets showed clustering of knee injury and OA
cases in overlapping but di 414 IPS adjustment (Figure 7A&B respectively). Both datasets showed clustering of knee injury and OA 415 cases in overlapping but distinguishable areas of high-dimensional proteomic space, though the 416 smaller groups (disease-free controls and inflammatory controls) were more evenly distributed. 417 smaller groups (disease-free controls and inflammatory controls) were more evenly distributed.

- 418
- Inflammation controls tended to segregate with a segment of the segregate with a segment of the patterns were also patterns were also been interested to the patterns were also been interested to the patterns were also been 419 reflected at the PC level (Figure 6F, Figure S6).

420 DISCUSSION

421 In the solution of the SomaScan assay for knee SF for the first time. We address a series of data
In this processing and analysis challenges that arise from proteomic quantification of SF using this
Intechnology. Based on 422 processing and analysis challenges that arise from proteomic quantification of SF using this
technology. Based on our investigations, we propose an optimal standardisation procedure for SF
and an assessment of the quality 423 procedure for SF
technology. Based on our investigations, we propose an optimal standardisation procedure for SF
and an assessment of the quality of the protein data using pre-defined approaches. Our aim was to
justify the 424 technology. Based on our investigation, the protein data using pre-defined approaches. Our aim was to
justify the best approach to minimize technical variation while maintaining biological variation in the
data, and thus t 425 justify the best approach to minimize technical variation while maintaining biological variation in the
data, and thus to develop a pipeline that could be applied to downstream analyses within STEpUP
OA and in subsequent p 426 justify the best approach to develop a pipeline that could be applied to downstream analyses within STEpUP
OA and in subsequent proteomic analyses of SF by others.
We identified a number of technical confounders, which all 427 428

429

dependent of the total analyses of SF by others.
We identified a number of technical confounders, which all affected, to a great or lesser extent, the
data structure. These included factors that related to the SF sample e. Ve identified a number of technical confounders, which a
data structure. These included factors that related to the
thaws, as well as potential confounders that could arise di 430 data structure. These included factors that related to the SF sample e.g. its age, number of freeze-
thaws, as well as potential confounders that could arise during the sample processing e.g. plate and
date of processing. 431 these was controlled for by adjustment or filtering (either sample or SOMAmer). Whilst our 432 to identify plate position and laboratory processing batch as additional confounding factors. Each of
these was controlled for by adjustment or filtering (either sample or SOMAmer). Whilst our
intention is to perform the p 433 do identify plate position and laboratory processing batch as additional confounding factors. Each of these was controlled for by adjustment or filtering (either sample or SOMAmer). Whilst our intention is to perform the p 434 these was controlled for by adjustment or filtering (either sample or SOMAmer). Whilst our
intention is to perform the primary analysis of STEpUP OA only in spun SF sample data, we also
included a number of unspun samples 435 Intention is to perform the primary analysis of STEpUP OA only in spun SF sample data, we also
included a number of unspun samples to test the generalizability of these to the larger dataset. In
doing so we calculated that 436 included a number of unspun samples to test the generalizability of these to the larger dataset. In
doing so we calculated that more stringent filtering would be needed when studying unspun, or
mixed spun/unspun SF collect 437 included a number of unspect to test the generalization, of these to the larger dataset in
doing so we calculated that more stringent filtering would be needed when studying unspun, or
mixed spun/unspun SF collections. We 438 doing mixed spun/unspun SF collections. We chose not to correct for blood staining (or HBA) or sample
volume as we felt that these could reflect important biological variation.
The finding that a large proportion of varian 439 440

441

mined span, impair of sensements are sincer instant for servers and staining (or HBA) or sample
volume as we felt that these could reflect important biological variation.
The finding that a large proportion of variance in The finding that a large proportion of variance in the data was driven
unexpected. This could have arisen as a result of technical confounding
the SF samples by cells e.g. by a failure to remove cells fully by centrifuga 442 The finality that a large proportion of that and alleged in the data was driven by intractment protein the
unexpected. This could have arisen as a result of technical confounding following contamination of
the SF samples b 443 the SF samples by cells e.g. by a failure to remove cells fully by centrifugation, or by cell lysis of those
cells at the time of aspiration e.g. by delay in spinning sample down. It could also be a true reflection
of cell 444 the SF sample state the time of aspiration e.g. by delay in spinning sample down. It could also be a true reflection
of cellular turnover within the joint as part of the disease process e.g. of infiltrating immune cells o 445 of cellular turnover within the joint as part of the disease process e.g. of infiltrating immune cells or native connective tissues. It could also reflect protein carried within microvesicles that are known to be increased 446 native connective tissues. It could also reflect protein carried within microvesicles that are known to
be increased in joint disease and which drive biology within and between joint tissues^[54, 55]. These
possibilities 447 native connective tissues. It could also reflect to reflect protein carried within and between joint tissues^[54, 55]. These
possibilities are currently being explored. There is a concern that if the IPS reflects true bio be increased in joint disease and which drive biology within and between joint tissues^[54, 55]. These
449 possibilities are currently being explored. There is a concern that if the IPS reflects true biology, then
450 adj 449 possibilities are currently being explored. There is a concern that if the IPS reflects true biology, then adjusting for it may compress true signals within the data. This is consistent with the reduction in correlation wi 450 correlation with immunoassay seen in the injury samples. On the other hand, subtle structures
within the data that reflect true molecular endotypes might be masked without removal of this
in the data that reflect true mole 451 within the data that reflect true molecular endotypes might be masked without removal of this
within the data that reflect true molecular endotypes might be masked without removal of this
19 452 with the data that reflect true molecular endotypes might be masked with be masked with be masked without removal of this contribution \mathbb{R}^n

453 454

455

signal. For this reason, the relevance of the IPS to clinical parameters and endotype clusters will be
addressed alongside one another in the primary analysis of STEpUP OA.
Our data demonstrate that, when properly processe different clinical groupings. Its quantitation quality is at least comparable/superior to other 'non-456 quantification of SF proteins which can (as a quality check, not a diagnostic one) broadly separate
different clinical groupings. Its quantitation quality is at least comparable/superior to other 'non-
standard' matrices e 457 different clinical groupings. Its quantitation quality is at least comparable/superior to other 'non-
standard' matrices e.g. urine/cerebrospinal fluid previously studied on this platform^[56-58]. Our
repeatability measur 458 and serum samples measured using SomaScan technology, where %CVs of 5% or less are standard' matrices e.g. urine/cerebrospinal fluid previously studied on this platform^[56-58]. Our
460 repeatability measures in pooled synovial fluid samples, with median %CVs of 11.25% for OA sample
461 replicates and 1 460 replicates and 12.42% for injury sample replicates, were higher than have been reported for plasma
and serum samples measured using SomaScan technology, where %CVs of 5% or less are
observed^[59]. However, our correlation 461 and serum samples measured using SomaScan technology, where %CVs of 5% or less are
observed^[59]. However, our correlation with immunoassays (median coefficient 0.81 for OA and 0.92
injury respectively) are as good or bet 462 and served^[59]. However, our correlation with immunoassays (median coefficient 0.81 for OA and 0.92
injury respectively) are as good or better than are typically observed in blood samples^[60, 61]. Our
data quality metr observed^[59]. However, our correlation with immunoassays (median coefficient 0.81 for OA and 0.92
464 injury respectively) are as good or better than are typically observed in blood samples^[60, 61]. Our
465 data qualit injury respectively) are as good or better than are typically observed in blood samples^[60, 61]. Our data quality metrics are comparable with those based on mass spectrometry or other quantitative immunoassays, where %CV 465 immunoassays, where %CVs of 10% or greater are recorded ^[62, 63]. Compared with these
technologies our data has higher dynamic range and sensitivity (as the technology can assay proteins
that are at very high as well as immunoassays, where %CVs of 10% or greater are recorded ^[62, 63]. Compared with these
467 technologies our data has higher dynamic range and sensitivity (as the technology can assay proteins
468 that are at very high as 467 that are at very high as well as low abundance), noting only proteins on a pre-defined (though very 468 469

470

that are at very high as well as low abundance), noting only proteins on a protein (though very)
large) protein list are included.
There are several limitations of this large study. The consortium collection was highly
het There are several limitations of this large study. The consortium collection was highly
heterogeneous, gathered from seventeen different studies, varying in disease severity and
phenotype, across several decades and from a 471 Theterogeneous, gathered from seventeen different studies, varying in disease severity and
phenotype, across several decades and from a number of countries without a unified pre-specified
sample processing protocol. This m 472 mentype, across several decades and from a number of countries without a unified pre-specified
sample processing protocol. This made distinguishing technical and biological variation difficult (as
was the case for the intr 473 phenotensing protocol. This made distinguishing technical and biological variation difficult (as
was the case for the intracellular protein score, which could reflect either variation in joint biology or
variation in sampl 474 sample processing procession and along analog collimitation and biology or
was the case for the intracellular protein score, which could reflect either variation in joint biology or
variation in sampling handling). A furth 475 wariation in sampling handling). A further limitation is that we analysed only a single matrix (SF) although this likely reflects activity in multiple joint tissues. The lack of paired cartilage/synovium/bone in STEpUP OA 476 variance in sampling manimizy. A function intrinsic matrix of matrix α single matrix (s), although this likely reflects activity in multiple joint tissues. The lack of paired cartilage/synovium/bone in STEpUP OA preven 477 cartilage/synovium/bone in STEpUP OA prevents us performing a direct integrated analysis using
RNAseq, for example, although it may be possible to extrapolate this from other existing datasets.
Other proteome-wide technolo 478 carting, a monographic in STEPUP OF performing a more integrated analysis using density of the proteome-wide technologies (such as LC-MS/MS, OLINK^[64]) could provide further validation on protein patterns within OA SF. P 479 Other proteome-wide technologies (such as LC-MS/MS, OLINK^[64]) could provide further validation
on protein patterns within OA SF. Paired plasma is also available for many individuals in STEpUP OA
but is yet to be analys Other proteome-wide technologies (such as LC-MS/MS, OLINK^[64]) could provide further validation
481 on protein patterns within OA SF. Paired plasma is also available for many individuals in STEpUP OA
482 but is yet to b 481 but is yet to be analysed. From previous experience we would predict that this matrix would show
low concordance with SF^[41, 65]. Others have used SomaScan to explore the plasma proteome in OA,
identifying diagnostic and 482 but is yet to be analyzed. From previous input its first predict that the instant them are in OA,
low concordance with $SF^{[41, 65]}$. Others have used SomaScan to explore the plasma proteome in OA,
identifying diagnostic a low concordance with SF^[41, 65]. Others have used SomaScan to explore the plasma proteome in OA,
484. identifying diagnostic and prognostic biomarkers, though this study did not study paired SF
485. samples^[34].
486. 484 $\text{samples}^{[34]}$.
 $\text{samples}^{[34]}$. 485 samples^[34] .
 486

486

20

- 487
- In summary, we present an evidence-based methodology pipeline for large scale proteomic analysis
on the SomaScan platform of SF, which has the potential to be a critical matrix for discovery science
and clinical translatio 488
- and clinical translation in OA. Our next step, the primary analysis of this dataset, seeks to answer 489
- definitively whether there are distinct discernible molecular endotypes in this common, yet poorly 490 definition of distinct d
- 491
- 492

493 Funding Statement:
494 The study was supp
495 Versus Arthritis (gram
496 21621, 20205), Gala
497 Somalogic (in kind cc
498 494 The Series Series (Spant number: 22473), Centre for OA Pathogenesis Versus Arthritis (grant numbers:
21621, 20205), Galapagos, Biosplice, Novartis, Fidia, UCB, Pfizer (non consortium member) and
Somalogic (in kind contribu 495 Versus 21621, 20205), Galapagos, Biosplice, Novartis, Fidia, UCB, Pfizer (non consortium member) and
Somalogic (in kind contributions).
Competing Interest Statement:
YD. TAP. PH. SL. AS. NKA. DF. BM. AMV. SK. VB. JMA and V 496 497

498

21621, Somalogic (in kind contributions).
21621, Sompeting Interest Statement:
2020, TAP, PH, SL, AS, NKA, DF, BM, AMV, SK, VB, JMA and VK declare no conflicts of interest. FW has Somalistic (in the competing Interest Statement:
Somalogic (in the statement:
Somalogic (in the contributions).
Somalogic (in the statement).
Somalogic (in the contributions). 499 **Competing Interest Statement:**
500 YD, TAP, PH, SL, AS, NKA, DF, BN
601 received consultancy fees from
502 (panel member) and Osteoarth
6503 fees from Arthro Therapeutics A
6504 member). UD has received con 500 YD, TAP, PH, SL, AS, NKA, DF, BM, AMV, SK, VB, JMA and VK declare no conflicts of interest. FW has 501 (panel member) and Osteoarthritis and Cartilage (Associate Editor). LSL has received consultancy
fees from Arthro Therapeutics AB, and is an advisory board member of AstraZeneca (non consortium
member). LJD has received co 502 (panel member), and Osteomannia and Osteoman Divideo Divideo Divideo Bersey, the material osteoman

fees from Arthro Therapeutics AB, and is an advisory board member of AstraZeneca (non consortium

member). LJD has receive 503 ferrementally and interacting the and advisory of a the anti-member of Arthro Thermannia member). UD has received consultancy fees from Nightingale Health PLC. TLV has no conflicts to declare with the exception of grant in 504 member). La that reception of grant income for STEpUP OA from industry partners (see above). RAM
is a shareholder of AstraZeneca. SB and JM are employees and shareholders of Novartis (consortium
members). MK has received s 505 is a shareholder of AstraZeneca. SB and JM are employees and shareholders of Novartis (consortium
members). MK has received support for attending the Gordon Research Conference, OARSI meeting,
International Cartilage Repai 506 is a shareholder of Astrazeneca. Shareholder of Astrazeneca. Shareholders and the members). MK has received support for attending the Gordon Research Conference, OARSI meeting,
International Cartilage Repair Society, Munst 507 mernational Cartilage Repair Society, Munster University, is a board member of the Dutch Arthritis
Society (Chair of Visitation Board), and has a leadership role at Osteoarthritis Research Society
International (Board of D 508 Society (Chair of Visitation Board), and has a leadership role at Osteoarthritis Research Society
International (Board of Directors Member). DAW has received consultancy fees from
GlaxoSmithKline plc, AKL Research & Develo 509 International (Board of Directors Member). DAW has received consultancy fees from
GlaxoSmithKline plc, AKL Research & Development Limited, Pfizer Ltd, Eli Lilly and Company, Contura
International, and AbbVie Inc, has recei 510 International (Board of Directors Member). Data the Trectors Consumery, the Anti-
International, and AbbVie Inc, has received honoraria for educational purposes from Pfizer Ltd and
AbbVie Inc, is a board member of UKRI (Di 511 International, and AbbVie Inc, has received honoraria for educational purposes from Pfizer Ltd and
AbbVie Inc, is a board member of UKRI (Director) and Versus Arthritis Advanced Pain Discovery
Platform.
Concention and Deci 512 AbbVie Inc, is a board member of UKRI (Director) and Versus Arthritis Advanced Pain Discovery
Platform.
Author contributions:
Conception and Design: TLV, FEW, LJD, PH, RAM, DP, SL, SB, LSL, AS, CTA, DF, BDMT, MK, TJW, DAW, 513 514

515

Platform.
Author contributions:
Conception and Design: TLV, FEW, LJD, PH, RAM, DP, SL, SB, LSL, AS, CTA, DF, BDMT, MK, TJW, DAW,
AMV. Analysis and interpretation of data: YD, TAP, LJD, FEW,TLV, PH, RAM, JM, SB, BDMT, LB. **Author co
Conceptic
AMV. Ana
Drafting A** 516 Author contributions:

517 Conception and Design

518 AMV. Analysis and in:

519 Drafting Article: TLV,

520 authors.

521 Acknowledgements: 517 Conception and Design: Terry 2007 (2007) (2007) 2007) 2007, 2007, 2007, 2007, 2007, 2007, 2007, 2009, 2009, 200
AMV. Analysis and interpretation of data: YD, TAP, LJD, FEW, TLV, PH, RAM, JM, SB, BDMT, LB.
Drafting Article: 518 AMY AMAY ANALY PROTECTS AND ALLOCATED AT A LATER AND THE UPPER STATISTIC CONTRIBUTION IS DETERMINED AN ARRY OF

Drafting Article: TLV, TAP, YD, LID, FEW. Critical revision of article: all authors. Final Approval: all

auth 519 520

521

authors.
 Acknowledgements:

We would like to express our gratitude and thanks to all cohorts and their participants who

contributed samples to STEpUP OA. We are grateful for the support from Floris Lafeber and Simon

M Address
Acknowl
We wou
Contribut
Mastberg 522 Acknowledgements:
523 We would like to e
524 contributed samples
525 Mastbergen (Utrecht
526 Research Centre (BRC
527 and not necessarily th 523 Contributed samples to STEpUP OA. We are grateful for the support from Floris Lafeber and Simon
Mastbergen (Utrecht Medical Centre). This work was also supported by the NIHR Oxford Biomedical
Research Centre (BRC) and the 524 Mastbergen (Utrecht Medical Centre). This work was also supported by the NIHR Oxford Biomedical
Research Centre (BRC) and the NIHR Nottingham BRC. The views expressed are those of the authors
and not necessarily those of t 525 Master Contre (BRC) and the NIHR Nottingham BRC. The views expressed are those of the authors
and not necessarily those of the NHS, the NIHR or the Department of Health. Tissue samples and/or
data obtained from the Oxford 526 and not necessarily those of the NHS, the NIHR or the Department of Health. Tissue samples and/or data obtained from the Oxford Musculoskeletal Biobank were collected with informed donor consent in full compliance with nat 527 and obtained from the Oxford Musculoskeletal Biobank were collected with informed donor
consent in full compliance with national and institutional ethical requirements, the UK Human Tissue
Act, and the Declaration of Helsi 528 consent in full compliance with national and institutional ethical requirements, the UK Human Tissue
Act, and the Declaration of Helsinki (HTA Licence 12217 and Oxford REC C 09/H0606/11). We thank
the Oxford Knee Surgery T 529 Act, and the Declaration of Helsinki (HTA Licence 12217 and Oxford REC C 09/H0606/11). We thank
the Oxford Knee Surgery Team including Andrew Price, William Jackson and Nicholas Bottomley and
our centre tissue coordinators 530 The Oxford Knee Surgery Team including Andrew Price, William Jackson and Nicholas Bottomley and
our centre tissue coordinators Louise Hill and Katherine Groves who coordinated this study. We
thank Charlotte Kerr for her ad 531 the Charlottenian Condinators Louise Hill and Katherine Groves who coordinated this study. We
thank Charlotte Kerr for her administrative support of the consortium at large.
The STEpUP OA Consortium author block includes: 532 533

534

Thank Charlotte Kerr for her administrative support of the consortium at large.
The STEpUP OA Consortium author block includes: University of Nottingham: Ana M. Valdes, David
A. Walsh, Michael Doherty, Vasileios Georgopoul The STEpUP OA Consortium author block includes: University of Nottingham:
A. Walsh, Michael Doherty, Vasileios Georgopoulos; Lund University: Staff 535 The STEPUP OF Consorting Oriental Consortium and STEPUP OF STEPUP OF Notice in Northern Author block includes: Note that Analyze Consortium and M. Valdes, D. Valdes, D. Valdes, D. Valdes, D. Valdes, D. Valdes, D. 20, 20, 2 536 A. Walsh, Michael Doherty, Vasileios Georgopoulos; Lund University: Staffan Larsson, L. Stefan

537 Toronto: Mohit Kapoor, Rajiv Gandhi, Anthony Perruccio, Y. Raja Rampersaud, Kim Perry; University
of Manchester: Tim Hardingham, David Felson; University of Oxford: Tonia L. Vincent, Thomas A.
Perry, Luke Jostins-Dean, Yun 538 of Manchester: Tim Hardingham, David Felson; University of Oxford: Tonia L. Vincent, Thomas A.
Perry, Luke Jostins-Dean, Yun Deng, Vicky Batchelor, Jennifer Mackay-Alderson, Gretchen Brewer,
Rose M. Maciewicz, Brian Marsde 539 Perry, Luke Jostins-Dean, Yun Deng, Vicky Batchelor, Jennifer Mackay-Alderson, Gretchen Brewer,
Rose M. Maciewicz, Brian Marsden, Nigel K. Arden, Philippa Hulley, Andrew Price, Stefan Kluzek,
Megan Goff, Vinod Kumar, James 540 Rose M. Maciewicz, Brian Marsden, Nigel K. Arden, Philippa Hulley, Andrew Price, Stefan Kluzek,
Megan Goff, Vinod Kumar, James Tey; Imperial College London: Fiona E. Watt, Andrew Williams,
Artemis Papadaki; University Coll 541 Megan Goff, Vinod Kumar, James Tey; Imperial College London: Fiona E. Watt, Andrew Williams,
Artemis Papadaki; University College Maastricht: Tim J. Welting, Pieter Emans, Tim Boymans,
Liesbeth Jutten, Marjolein Caron, Guu 542 Meranis Papadaki; University College Maastricht: Tim J. Welting, Pieter Emans, Tim Boymans,
Liesbeth Jutten, Marjolein Caron, Guus van den Akker; University of Western Ontario: C. Thomas
Appleton, Trevor B. Birmingham, J. 543 Liesbeth Jutten, Marjolein Caron, Guus van den Akker; University of Western Ontario: C. Thomas
Appleton, Trevor B. Birmingham, J. Daniel Klapak; Biosplice: Sarah Kennedy, Jeymi Tambiah; Fidia:
Devis Galesso, Nicola NK; Som 544 Appleton, Trevor B. Birmingham, J. Daniel Klapak; Biosplice: Sarah Kennedy, Jeymi Tambiah; Fidia:
Devis Galesso, Nicola NK; SomaLogic: Joe Gogain, Darryl Perry, Anna Mitchel, Ela Zepko; Novartis:
Sophie Brachat, Joanna Mit 545 546 547

548

Devis Galesso, Nicola NK; SomaLogic: Joe Gogain, Darryl Perry, Anna Mitchel, Ela Zepko; Novartis:
Sophie Brachat, Joanna Mitchelmore, Juerg Gasser, Lori Jennings; UCB: Waqar Ali.
TLV directs the Centre for OA pathogenesis Sophie Brachat, Joanna Mitchelmore, Juerg Gasser, Lori Jennings; UCB: Waqar Ali.
TLV directs the Centre for OA pathogenesis (grant numbers 21612 and 20205) and has additional
grant support from Versus Arthritis, the Europe TLV directs the Centre for OA pathogenesis (grant numbers 21612 and 20205) and has additional grant support from Versus Arthritis, the European Research Council, the Medical Research Council and FOREUM. LJD is supported by 549 THE MOREUM. THE CENTRE FOR PERICY OF THE MORET INTEREDUATION and FOREUM. LID is supported by a Wellcome trust fellowship grant 208750/Z/17/Z and Kennedy
Trust for Rheumatology Research for the present manuscript. LID is al 550 gram supper from Versus Arthritis, Arthritis, from trusted are the MRC and Kennedy
Trust for Rheumatology Research for the present manuscript. LJD is also supported by grants from
the MRC and the Helmsley Charitable Trust. 551 Trust for Rheumatology Research for the present manuscript. LJD is also supported by grants from
the MRC and the Helmsley Charitable Trust. FEW is supported by a UKRI Future Leaders Fellowship
(MRC number: MR/S016538/1 and 552 The MRC and the Helmsley Charitable Trust. FEW is supported by a UKRI Future Leaders Fellowship
(MRC number: MR/S016538/1 and MR/S016538/2). FW, NKA and SK are members of the Centre for
Sport, Exercise and Osteoarthritis R 553 (MRC number: MR/S016538/1 and MR/S016538/2). FW, NKA and SK are members of the Centre for
Sport, Exercise and Osteoarthritis Research Versus Arthritis (grant number 21595). MK is supported
by grants from CIHR, NSERC, The A 554 Sport, Exercise and Osteoarthritis Research Versus Arthritis (grant number 21595). MK is supported
by grants from CIHR, NSERC, The Arthritis Society Canada, Krembil Foundation, CFI, Canada Research
Chairs program, and has 555 by grants from CIHR, NSERC, The Arthritis Society Canada, Krembil Foundation, CFI, Canada Research
Chairs program, and has received support from the University Health Network Foundation, Toronto
for the present manuscript. 556 Chairs program, and has received support from the University Health Network Foundation, Toronto
for the present manuscript. TJW is supported by grants from NWO-TTW Perspectief (#P15-23),
Stichting de Weijerhorst and ReumaN 557 For the present manuscript. TJW is supported by grants from NWO-TTW Perspectief (#P15-23),
Stichting de Weijerhorst and ReumaNederland (LLP14) for the present manuscript, and is a
shareholder of Chondropeptix BV. BDMT is s 558 Stichting de Weijerhorst and ReumaNederland (LLP14) for the present manuscript, and is a
shareholder of Chondropeptix BV. BDMT is supported through the United Kingdom Medical
Research Council programme (grant MC UU 00002/2 559 Shareholder of Chondropeptix BV. BDMT is supported through the United Kingdom Medical
Research Council programme (grant MC UU 00002/2). For the purpose of open access, the authors
have applied a Creative Commons Attributio 560 Shareholder of Chondropeptin BV. Button in Engineer interaction in the Inglesia interaction
Research Council programme (grant MC UU 00002/2). For the purpose of open access, the authors
have applied a Creative Commons Attr 561 Research Council programme (grant MC UC BY) license to any Author Accepted Manuscript
version arising. LB is supported by grants from Kennedy Trust for Rheumatology Research (grant
number 171806) and UK Medical Research Co 562 version arising. LB is supported by grants from Kennedy Trust for Rheumatology Research (grant
number 171806) and UK Medical Research Council (grant MC UU 00002/2). DAW is supported by
grants from Pfizer Ltd, UCB Pharma, O 563 version arising. LB is supported by grants from Trust from Hammer, there is incrementing, increment (grant
number 171806) and UK Medical Research Council (grant MC UU 00002/2). DAW is supported by
grants from Pfizer Ltd, U 564 manus 171806) and 18 Medical Research Company, Council (grant MC UU 0002), 2000 is supported by
grants from Pfizer Ltd, UCB Pharma, Orion Corporation, GlaxoSmithKline Research and
Data Access:
In accordance with the STEpUP 565 566 567

Bevelopment, and Eli Lilly and Company, Versus Arthritis, UKRI, Nuffield Foundation.
 Data Access:

In accordance with the STEpUP OA Consortium Agreement and the Data Access and Publication
Group,

protein and clinical d Data Access:

In accordance with the STEpUP OA Consortium Agreement and the Data Access

Group,

protein and clinical data will be available for bone fide research relating to osteoarth

analisation to the STEPUR OA Data A 569 570

568 **Data Access:**
569 In accordance
570 Group,
571 protein and c
572 application to
573 analyses are i Group,
protein and clinical data will be available for bone fide research relating to osteoarthritis through an
application to the STEpUP OA Data Access and Publication group once the discovery and replication
analyses are protein
applicat
analyse
(to be c 571 application to the STEpUP OA Data Access and Publication group once the discovery and replication analyses are in press and if it does not infringe patent position. This may be subject to an access fee
(to be confirmed).
E 572 573 574

575

analyses are in press and if it does not infringe patent position. This may be subject to an access fee

(to be confirmed).
 Ethical Approval:

The ethical approval reference numbers for individual participating cohorts analyses are in press and it is associated increasing patent position. This may be subject to an access fee to
(to be confirmed).
The ethical approval reference numbers for individual participating cohorts are provided in (the commonly).
Ethical Approval:
The ethical approv
In addition, a Unive
Sunnlementary Da 576 Ethical Approval:

577 The ethical approv

578 In addition, a Univ

579 S80 Supplementary D

581 Code availability 577 In addition, a University CUREC approval was granted for the study (details in Methods).
 Supplementary Data:

Code availability https://github.com/dengyun-git/STEpUp QC Paper. For access to primary data 578

579

Supplementary Data:
In addition, a University Cup and Supplementary Data:
In addition, and the study of the study (details in Methods). The study of the study of the study of the study 580 Supplementary Data:
581 Code availability <u>http</u>
= 581 $\frac{1}{2}$

582

583

used in this analysis, see Data Access section.
 Patient and Public Involvement Statement:

People with lived experience of osteoarthritis have been involved in the design of this project. A

patient research panel was i **Patient and Public Involvement Statement:**
585 People with lived experience of osteoarthri
586 patient research panel was involved in di
587 February 2020 (invited to the Centre for O:
588 part of its involvement activiti 585 patient research panel was involved in discussing and inputting on the STEpUP OA project in
February 2020 (invited to the Centre for Osteoarthritis Pathogenesis Versus Arthritis in Oxford, as
part of its involvement activi 586 patient research parameters in Osteo arthritis Pathogenesis Versus Arthritis in Oxford, as
part of its involvement activities). Aspects relevant to the development of the project were further
discussed with the panel in Ju 587 part of its involvement activities). Aspects relevant to the development of the project were further
discussed with the panel in July 2022. The working groups for the consortium include one focused
on patient involvement a 588 part of iscussed with the panel in July 2022. The working groups for the consortium include one focused
on patient involvement and engagement. A lay summary is included in the appendix of our publicly
available analysis pl 589 and particular in the panel in the consortion of the consortion particle in the appendix of our publicly available analysis plan. A short video about the project was produced and is available on our website: https://www.ke 590 available analysis plan. A short video about the project was produced and is available on our website: https://www.kennedy.ox.ac.uk/oacentre/stepup-oa. In addition, the various constituent cohorts contributing to STEpUP OA 591 available analysis plan. A short video about the project was produced and is available on our
website: https://www.kennedy.ox.ac.uk/oacentre/stepup-oa. In addition, the various constituent
cohorts contributing to STEpUP OA 592 website: https://www.kennedy.org/website.org/website.org/website/stepsite.org/website/stepup-oa. In addition, the various constitution
constitutions constituting to STEpUP-OA also typically have lay or patient members on t 593 committees.
committees. 594

596

595 **Figures/illustrations:**
596 **Figure 1.** Assessment
598 R^2 across all protein
599 respectively. Assessme
600 measured by the SO
601 normalisation steps **597 Figure 1.** Assessment of the effects of each standardisation step on (A) mean %CV and (B) mean R² across all proteins for pooled sample replicates, stratified by OA and acute knee injury respectively. Assessment of R^2 across all proteins for pooled sample replicates, stratified by OA and acute knee injury

respectively. Assessment of Pearson correlation coefficients between protein expression in samples

600 measured by the SOMAs 599 measured by the SOMAscan platform and by prior immunoassay for nine select proteins across
normalisation steps for (C) OA and (D) acute knee injury. The normalisation steps included
hybridisation normalisation (HN), plate 600 normalisation steps for (C) OA and (D) acute knee injury. The normalisation steps included
hybridisation normalisation (HN), plate scaling using plasma calibrators (PS), median signal
normalisation (MN) and calibration usi 601 normalisation normalisation (HN), plate scaling using plasma calibrators (PS), median signal
normalisation (MN) and calibration using plasma calibrators (PC). Correlation between the RFUs
(SOMAscan) and absolute concentrat 602 603 604

hormalisation (MN) and calibration using plasma calibrators (PC). Correlation between the RFUs
(SOMAscan) and absolute concentrations for the nine proteins across the two methods are shown.
RFUs, relative fluorescence uni (SOMAscan) and absolute concentrations for the nine proteins across the two methods are shown.
RFUs, relative fluorescence units; %CV, % coefficient of variation; osteoarthritis, OA; Activin A, Inhibin
beta A chain; FGF2, (SOMASCAN) and absolute concentrations for the nine proteins across the internet as a chain; FGF2, Fibroblast growth factor 2; IL6, Interleukin-6; IL8, Interleukin-8; MCP1, C-C mo
chemokine 2; MMP3, Stromelysin-1; TGFβ1, T 605 RFUS, CHANGE THE CHANGE TO THE CHANGE TO THE CHANGES (18, Interleukin-8; MCP1, C-C motif
chemokine 2; MMP3, Stromelysin-1; TGFβ1, Transforming growth factor beta-1; TIMP1, Tissue
inhibitor of metalloproteinase 1; TSG6, Tu 606 chemokine 2; MMP3, Stromelysin-1; TGF β 1, Transforming growth factor beta-1; TIMP1, Tissue
inhibitor of metalloproteinase 1; TSG6, Tumor necrosis factor-inducible gene 6.
Figure 2. (A) Variation explained (%) by the t 607 608

609

chemokine 2; MMP3, Stromelysin-1; TGFβ1, Transforming growth factor beta-1; TIMP1, Tissue
inhibitor of metalloproteinase 1; TSG6, Tumor necrosis factor-inducible gene 6.
Figure 2. (A) Variation explained (%) by the top 10 Figure 2. (A) Variation explained (%) by the top 10 PCs derived from the standa
proteomic data. (B) Correlation between PC1 and protein abundance, with
proteins (albumin, a soluble serum protein, and LDH, an intracellular 610 **Figure 2.** (A) Variation explained (%) by the top 10 PCs derived from the standardised log abundance proteomic data. (B) Correlation between PC1 and protein abundance, with two high-abundance proteins (albumin, a sol 611 proteins (albumin, a soluble serum protein, and LDH, an intracellular protein) marked. Protein
abundance is calculated as the standardized RFU for each protein adjusted by the protein's dilution
factor used in the SomaScan 612 proteins (albumin, a solution protein, and LD, an intrinsic protein adjusted by the protein's dilution
factor used in the SomaScan assay (the "dilution bin"). (C) Comparison of variation explained (%) by
PC1 between 18 pai 613 614 FC1 between 18 pairs of SF samples that were centrifuged (spun) or not (unspun) after aspiration
and prior to freezing, with paired samples from the same participant joined by separate lines. Red
lines show samples that ha 615 and prior to freezing, with paired samples from the same participant joined by separate lines. Red
lines show samples that had an increased PC1 prior to spinning, and the green line where it was
decreased. Correlation betw 616 and prior to freezing, that pairs samples from the same participant jointed by the same direct and decreased. Correlation between PC1 and intracellular protein score (D) before and (E) after IPS adjustment. (F) Variation e 617 decreased. Correlation between PC1 and intracellular protein score (D) before and (E) after IPS
adjustment. (F) Variation explained by the top 10 PCs derived from the batch corrected and IPS
adjusted log abundance proteomi 618 adjustment. (F) Variation explained by the top 10 PCs derived from the batch corrected and IPS
adjusted log abundance proteomic data. In all cases, correlation is measured using the Pearson
correlation coefficient. IPS, In 619 adjusted log abundance proteomic data. In all cases, correlation is measured using the Pearson
correlation coefficient. IPS, Intracellular Protein Score; PC, principal component; LDH, Lactate
dehydrogenase.
Figure 3. (A) D 620 correlation coefficient. IPS, Intracellular Protein Score; PC, principal component; LDH, Lactate
dehydrogenase.
Figure 3. (A) Distribution of the second principal component (PC2) derived from the standardised log
abundance 621 622

623

dehydrogenase.
 Figure 3. (A) Distribution of the second principal component (PC2) derived from the standardised log

abundance data, showing a bimodal distribution. (B) UMAP visualisation of two reduced dimensions

(D1 Figure 3. (A) Dist
abundance data,
(D1 and D2) of
bimodal protein Figure 3. (A) Distribution of the second principal component (PC2) derived from the standardised log

625 abundance data, showing a bimodal distribution. (B) UMAP visualisation of two reduced dimensions

626 (D1 and D2) of 625 (D1 and D2) of the top PCs of the standardised log abundance data. (C) Example of a strongly
bimodal protein measurement, TSG101, RFU (y-axis) against Oxford laboratory processing order (x-
axis) and coloured by laboratory 626 bimodal protein measurement, TSG101, RFU (y-axis) against Oxford laboratory processing order (x-
axis) and coloured by laboratory processing batch (with only points within the same processing batch
connected by lines). Not 627 processed and re-assayed, showing that bimodal status changed after laboratory re-processing. (E) 628 strong among sample batches that were processed later in processing order. (D) The same example 629 when processing batch changed, and only rarely within processing batch. This effect was particularly
strong among sample batches that were processed later in processing order. (D) The same example
protein measurement for t 630 when processing batch changed, and only rarely rarely meaning batch changed are into processing the same example
protein measurement for three independent SF samples before (original) and after they were re-
processed and 631 protein measurement for three independent SF samples before (original) and after they were re-
processed and re-assayed, showing that bimodal status changed after laboratory re-processing. (E)
Distribution of PC2 derived f 632 protein measurement for the batch corrected log abundance data, with the now near-identical distributions of the two
bimodal signal status groups shown as colored lines, (H) UMAP visualisation on two reduced
 25 633 preceduation of PC2 derived from standardised log abundance data, showing the two probability
density functions of the Gaussian Mixture Model used to classify samples into the two bimodal signal
status groups. (F) UMAP vis 634 Distribution of the Gaussian Mixture Model used to classify samples into the two bimodal signal
status groups. (F) UMAP visualisation of two reduced dimensions (D1 and D2) of the top PCs of the
standardised log abundance d 635 status groups. (F) UMAP visualisation of two reduced dimensions (D1 and D2) of the top PCs of the
standardised log abundance data, colored by the inferred bimodal signal status. (G) Histogram of PC2
of the batch corrected 636 standardised log abundance data, colored by the inferred bimodal signal status. (G) Histogram of PC2 637 638 bimodal signal status groups shown as colored lines, (H) UMAP visualisation on two reduced 639 bimodal signal status groups shown as colored lines, (H) UMAP visualisation on two reduced

640 641 642

643

inferred bimodal signal status. RFUs, relative fluorescence units; PC, Principal Component; TSG101,
Tumor susceptibility gene 101 protein; UMAP, Uniform Manifold Approximation and Projection.
Figure 4. Correlation between Tumor susceptibility gene 101 protein; UMAP, Uniform Manifold Approximation and Projection.
 Figure 4. Correlation between SOMAscan relative frequency abundance (RFU) and abundance

measured using orthogonal immunoassays Figure 4. Correlation between SOMAscan relative frequency abundance (RFU) and abundance measured using orthogonal immunoassays for 9 selected proteins at different stages of SOMAscan data processing, for (A) osteoarthriti Figure 4. Correlation between SOMAscan relative frequency abundance (RFU) and abundance
645 measured using orthogonal immunoassays for 9 selected proteins at different stages of
646 SOMAscan data processing, for (A) osteoa 645 SOMAscan data processing, for (A) osteoarthritis and (B) acute knee injury samples. Correlation was
measured using the Pearson correlation coefficient. Raw data refers to the raw RFUs without any
processing, optimised stan 646 measured using the Pearson correlation coefficient. Raw data refers to the raw RFUs without any
processing, optimised standardisation was the data standardised using our selected optimal
normalization steps (Figure 1), pro 647 measured using the Pearson correlation correlation correlation correlation correlation steps (Figure 1), processed without IPS adjustment refers to data that has been batch corrected for bimodal signal status and plate but 648 processing, optimised standardisation was the data standardised using the selected standardised normalization steps (Figure 1), processed without IPS adjustment refers to samples that have undergone both batch correction a 649 normalization steps (Figure 2), processed with the angles means there is anticipated for bimodal signal status and plate but not IPS adjusted, and processed with IPS adjustment refers to samples that have undergone both ba 650 651 652

653

adjustment refers to samples that have undergone both batch correction and IPS adjustment. IPS,
Intracellular Protein Score; Protein name abbreviations as in Figure 1.
Figure 5. Overview of the final data processing and qu adjustment referred samples that have undergone both batch correction and to sagaritant have
Intracellular Protein Score; Protein name abbreviations as in Figure 1.
Figure 5. Overview of the final data processing and qua Intracellular Protein Scores Introduction of the state of the final data processing and quality cont
SOMAscan data used by the STEpUP OA consortium, broken down int
(yellow box), technical confounder correction (blue box) Figure 5. Overview of the final data processing and quality control pipeline for synovial fluid
655 SOMAscan data used by the STEpUP OA consortium, broken down into three stages: standardisation
656 (yellow box), technica 655 (yellow box), technical confounder correction (blue box) and filtering (green box). More details on filtering thresholds, and the number removed by each filter, can be found in Supplementary Table S4.
Figure 6. Visualisati 656 657 658

Filtering thresholds, and the number removed by each filter, can be found in Supplementary Table S4.

Figure 6. Visualisation of selected pre-defined confounders against select principal components of

the batch corrected, Figure 6. Visualisation of selected pre-defined confounders against select principal components of
the batch corrected, filtered, IPS adjusted data. (A) The average value of PC9 (most strongly
associated with plate positio **659 Figure 6.** Visualisation of selected pre-defined confounders against select principal components of the batch corrected, filtered, IPS adjusted data. (A) The average value of PC9 (most strongly associated with plate 660 associated with plate position) by sample well position, (B-F) visualisation of the two PCs most
strongly associated with each confounder, coloured by confounder value. Pre-defined confounders
shown are (B) blood staining 661 strongly associated with each confounder, coloured by confounder value. Pre-defined confounders
shown are (B) blood staining grade of sample after aspiration assessed by visual inspection, (C)
volume of sample taken during 662 shown are (B) blood staining grade of sample after aspiration assessed by visual inspection, (C) volume of sample taken during aspiration, (D) age of the sample in years, measured from aspiration to sample processing at Ox 663 shown are (E) blood stamling grade of stample after application afterward, instanting control stample processing at Oxford, (E) the number of times the sample was thawed and re-
frozen before sample processing at Oxford, (664 to sample processing at Oxford, (E) the number of times the sample was thawed and re-
frozen before sample processing at Oxford, (F) the disease group of the sample (osteoarthritis [OA],
acute knee injury [Injury], healthy 665 666 667

668

disease group. These groups were osteoarthritis (OA, acute knee injury (injury), healthy controls, from a carry contingent processing at Oxford, (F) the answer group of the sample (osteom ministery),
acute knee injury [Injury], healthy control, inflammatory arthritis control).
Figure 7. UMAP visualisation of two reduced Figure 7. UMAP visualisation of two reduced dimensions (D1 and D2)
abundance data with (A) and without (B) IPS adjustment followed
disease group. These groups were osteoarthritis (OA, acute knee injury
inflammatory arthrit Figure 7. UMAP visualisation of two reduced dimensions (D1 and D2) of the top PCs of the log
670 abundance data with (A) and without (B) IPS adjustment followed by filtering, coloured by
671 disease group. These groups wer 670 disease group. These groups were osteoarthritis (OA, acute knee injury (injury), healthy controls,
inflammatory arthritis controls.
UMAP, Uniform Manifold Approximation and Projection.
Figure S1. Consortium structure, as 671 672

673

674

inflammatory arthritis controls.

UMAP, Uniform Manifold Approximation and Projection.

Figure S1. Consortium structure, as working groups. Distinct working groups oversaw key activities

according to pre-defined Terms of inflammatory arthritis controls.

UMAP, Uniform Manifold Approximation and Projection.

Figure S1. Consortium structure, as working groups. Distinct working groups oversaw key activities

according to pre-defined Terms of Figure S1. Consortium structure, as working groups. Dis
according to pre-defined Terms of Reference (available
Watt; AV, Ana Valdes; LJD, Luke Jostins-Dean; RM, Rose N
Eigure S2. Assessment of assay repeatability using poo Figure S1. Consortium structure, as working groups. Distinct working groups oversaw key activities
676 according to pre-defined Terms of Reference (available on request). TV, Tonia Vincent; FW, Fiona
677 Watt; AV, Ana Vald 676 677

678

according to pre-defined Terms of Addressian (arabitate on request). Thy terms intermy they tend
Watt; AV, Ana Valdes; LJD, Luke Jostins-Dean; RM, Rose Maciewicz.
Figure S2. Assessment of assay repeatability using pooled s Figure S2. Assessment of assay repeatability using pooled samples
with (A) knee OA and (B) acute knee injury, measured by the coe
include the repeatability of the standard processed pooled samples
Repeats'), pooled samples Figure S2. Assessment of assay repeatability using pooled samples of synovial fluid from participants
680 with (A) knee OA and (B) acute knee injury, measured by the coefficient of variation (%CV). These
681 include the re 680 include the repeatability of the standard processed pooled samples included on every plate ('Sample
Repeats'), pooled samples which had been repeatedly freeze-thawed ('Freeze Thaw') prior to
processing and an OA pool aliqu 681 Frace the repeats'), pooled samples which had been repeatedly freeze-thawed ('Freeze Thaw') prior to
processing and an OA pool aliquot that had been freshly enzyme digested with stored hyaluronidase
26 682 processing and an OA pool aliquot that had been freshly enzyme digested with stored hyaluronidase

26 683 processing and an OA pool aliquot that had been freshly enzyme digested with stored hyaluronidase

684 685

686

('Reprocessed'). Dotted vertical lines show the maximum %CV for 80% of proteins for each group.

Figure S3. Top 2 principal components of (A) non-IPS adjusted and (B) IPS adjusted log RFU of the 18

pairs of centrifuged (s Figure S3. Top 2 principal components of (A) non-IPS adjusted and (B) IPS adjusted log RFU of the
pairs of centrifuged (spun) and non-centrifuged (unspun) SF samples. Samples are coloured by s
status and paired samples are Figure S3. Top 2 principal components of (A) non-IPS adjusted and (B) IPS adjusted log RFU of the 18
688 pairs of centrifuged (spun) and non-centrifuged (unspun) SF samples. Samples are coloured by spin
689 status and pai 688 status and paired samples are linked by lines. Measures of differential abundance (Cohen's d) and
Pearson correlation coefficient (rho) between spun and unspun samples for (C) non-IPS adjusted and
(D) IPS adjusted log RFU 689 status and paired samples are linked by lines. Measures of differential abundance (Cohen's d) and
Pearson correlation coefficient (rho) between spun and unspun samples for (C) non-IPS adjusted and
(D) IPS adjusted log RFU. 690 (D) IPS adjusted log RFU. Samples are coloured depending on their significance (Benjamini-Hochberg
adjusted $p < 0.05$) on the two measures: Different Means corresponds to a significant difference in
means in a paired t-te 691 (D) IPS adjusted p< 0.05) on the two measures: Different Means corresponds to a significant difference in
means in a paired t-test and Correlated corresponds to a significant correlation in a Pearson
correlation test. IPS, 692 means in a paired t-test and Correlated corresponds to a significant correlation in a Pearson
correlation test. IPS, intracellular protein score; PC, principal component; SF, synovial fluid; RFU,
relative fluorescence unit 693 694 695

696

means in a pairs in a pairs and Correlation score; PC, principal component; SF, synovial fluid; RFU,
relative fluorescence unit.
Figure S4. Boxplots showing the correlation between visual blood staining grade of SF at the relative fluorescence unit.
 Figure S4. Boxplots showing the correlation between visual blood staining grade of SF at the time of

sample collection and the blood analyte, HBA, in non-IPS adjusted data in (A) all samples Figure S4. Boxplots showin
Sample collection and the
Samples and (E) acute kn
Samples and (F) acute kne Figure S4. Boxplots showing the correlation between visual blood staining grade of SF at the time of
698 sample collection and the blood analyte, HBA, in non-IPS adjusted data in (A) all samples, (C) OA
699 samples and (E 698 samples and (E) acute knee injury samples, and in IPS adjusted data in (B) all samples, (D) OA samples and (F) acute knee injury samples. Spearman correlation coefficients measuring rank-based correlation considering visu 699 samples and (F) acute knee injury samples. Spearman correlation coefficients measuring rank-based
correlation considering visual blood staining as an ordinal variable are shown. 443 OA samples had
blood staining grade 1 (n 700 correlation considering visual blood staining as an ordinal variable are shown. 443 OA samples had
blood staining grade 1 (no blood detected, 75% among the 588 total samples with blood staining
records). HBA, haemoglobin A 701 702 703

704

blood staining grade 1 (no blood detected, 75% among the 588 total samples with blood staining
records). HBA, haemoglobin A; IPS, intracellular protein score; SF, synovial fluid.
Figure S5. (A) Assessment of assay repeatab blood statement of assay repeatability after optimised quality control procedures measured
 Figure S5. (A) Assessment of assay repeatability after optimised quality control procedures measured

using the cumulative distr Figure S5. (A) Assessment of assay repeatability after optimised quality control posing the cumulative distribution of the coefficient of variation (%CV) on pocsample Repeats) and pooled acute knee Injury samples (Injury S **Figure S5.** (A) Assessment of assay repeatability after optimised quality control procedures measured

706 using the cumulative distribution of the coefficient of variation (%CV) on pooled OA samples (OA

707 Sample Repe 706 Sample Repeats) and pooled acute knee Injury samples (Injury Sample Repeats) separately. 80% of proteins had a %CV less than 16.85% and 17.57% in the OA and acute knee injury pools (blue and red dotted lines respectively) 707 proteins had a %CV less than 16.85% and 17.57% in the OA and acute knee injury pools (blue and red dotted lines respectively). (B) The proportion of variation that was estimated to be non-technical, measured by R^2 for 708 proteins had a core entirely. (B) The proportion of variation that was estimated to be non-technical, measured by R² for OA and acute knee injury sample repeats separately. 80% of proteins had R² values greater than 88 709 dotted lines respectively). (B) The proportion of variation that was estimated to be non-technical, measured by R^2 for OA and acute knee injury sample repeats separately. 80% of proteins had R^2 values greater than 8 measured by R²
values greater th
respectively).
Figure S6. Visual
(A) non-filtered l measured by R^2 for OA and acute knee injury sample repeats separately. 80% of proteins had R^2

values greater than 88.27% and 84.33% in the OA and knee injury pools (blue and red dotted lines

respectively).
 Figur 711 712

713

values greater than 88.27% and 88.27% in the OA and red dotted in

Figure S6. Visualisation of pre-defined technical confounders by select principal components of the

(A) non-fi respectively).

Figure S6. Vis

(A) non-filtere

Visualisation confounder va

(which was re Figure S6. Visualisation of pre-defined technical confounders by select principal components of the

(A) non-filtered IPS adjusted (B) filtered non-IPS adjusted and (C) non-filtered non-IPS adjusted data.

716 Visualisatio 715 Visualisation of the two PCs most strongly associated with each confounder (colours correspond to confounder value). Confounders include plate position (mean of PC8), blood staining grade of sample (which was performed imm 716 confounder value). Confounders include plate position (mean of PC8), blood staining grade of sample
(which was performed immediately after aspiration from the joint by visual inspection), volume of
sample taken during aspi 717 (which was performed immediately after aspiration from the joint by visual inspection), volume of
sample taken during aspiration, age of the sample in years from aspiration to processing, the number
of times the sample had 718 sample taken during aspiration, age of the sample in years from aspiration to processing, the number
of times the sample had been thawed and re-frozen, the disease group of the sample (knee
OA, acute knee injury, healthy c 719 of times the sample had been thawed and re-frozen, the disease group of the sample (knee
OA, acute knee injury, healthy control, inflammatory arthritis control). The association between
each PC and confounder is shown in t 720 721 722

723

of the same the sample had been thanks and re-frozen, the latents group of the sample (had confounder is shown in the Table S7.
Figure S7. Pairwise scatter plots (off-diagonal) and histograms (diagonal) of the top five pri Proposed internation, increasing terms of the Table S7.
 Figure S7. Pairwise scatter plots (off-diagonal) and histograms (diagonal) of the top five principal

components of standardised log abundance, (A) before and (B) Figure S7. Pairwise scatter plots (off-diagonal) a
components of standardised log abundance, (A) bimodal signal status, coloured by bimodal signal
effect of bimodal signal Figure S7. Pairwise scatter plots (off-diagonal) and histograms (diagonal) of the top five principal

725 components of standardised log abundance, (A) before and (B) after batch correction for plate and

726 bimodal signa 725 bimodal signal status, coloured by bimodal signal status. Batch correction effectively removed the
effect of bimodal signal status on the top PCs. 726 effect of bimodal signal status on the top PCs.
27 727 effect of binding status on the top PCs.
27
27

- 828 45.
- 45. Gold, L., et al., Aptamer-based multiplexed proteomic technology for biomarker discovery.

PLOS One, 2010. 5(12): p. e15004.

46. Schneider, D.J., et al., Chapter 8 SOMAmer reagents and the SomaScan platform:

Chemic 829 PLoS One, 2010. 5(12): p. e15004.

830 46. Schneider, D.J., et al., Chapter

831 Chemically modified aptamers a

832 proteomics, in RNA Therapeutics,

833 2022, Academic Press. p. 171-260.

834 47. Harris, P.A., et al. 830 Chemically modified aptamers and their applications in therapeutics, diagnostics, and
proteomics, in RNA Therapeutics, P.H. Giangrande, V. de Franciscis, and J.J. Rossi, Editors.
2022, Academic Press. p. 171-260.
47. Harri 831 Proteomics, in RNA Therapeutics, P.H. Giangrande, V. de Franciscis, and J.J. Rossi, Editors.
2022, Academic Press. p. 171-260.
Harris, P.A., et al., *The REDCap consortium: Building an international community of software*
 832 833
- protes)
2022, Academic Press. p. 171-260.
Harris, P.A., et al., *The REDCap consortium: Building an international community of software
platform partners. J Biomed Inform, 2019. 95: p. 103208.
Georgopoulos, V., et al., <i>Th* Eventy, D.A., et al., *The REDCap con*
Harris, P.A., et al., *The REDCap con*
platform partners. J Biomed Inform
Georgopoulos, V., et al., *The patie*
iterature review and meta-analysis
Candia, J., et al., *Assessment of V* 834 835
- platform partners. J Biomed Inform, 2019. 95: p. 103208.
48. Georgopoulos, V., et al., *The patient acceptable symptom state for knee pain a systematic literature review and meta-analysis. Osteoarthritis and Cartilage, 2* platform partners. J Biomed Inform, 2019. 33. p. 103208.
Georgopoulos, V., et al., *The patient acceptable sympton*
literature review and meta-analysis. Osteoarthritis and Ca
Candia, J., et al., Assessment of Variability i 836 837
- 838
- Vanda, 1., et al., Assessment of Variability in the SOMAscan Assay. Scientific Reports, 2017.

49. Candia, J., et al., Assessment of Variability in the SOMAscan Assay. Scientific Reports, 2017.

50. ComBat: Adjust for batc 840 841
- nerature review and meta-analysis. Osteoarthritis and Cartilage, 2021. 29: p. 332.
Candia, J., et al., Assessment of Variability in the SOMAscan Assay. Scientific Repe
7.
ComBat: Adjust for batch effects using an empirical 49.

49. ComBat: Adjust for batch effects using an empirical Bayes framework. 2022 [cited 07-07-23];

49. Available from: https://rdrr.io/bioc/sva/man/ComBat.html.

51. Sward, P., et al., Cartilage and bone markers and in 839 7.

840 50. Co

841 Av

842 51. Sw

843 *syl*

844 Os

845 52. Sw

846 Available from: https://rdrr.io/bioc/sva/man/ComBat.html.

51. Sward, P., et al., *Cartilage and bone markers and inflammatory cytokines are increased in*
 *synovial fluid in the acute phase of knee injury (hemarthrosis)--*Sward, P., et al., *Cartilage and bone markers and inflamm*
synovial fluid in the acute phase of knee injury (hemarthin
Osteoarthritis Cartilage, 2012. **20**(11): p. 1302-8.
Sward, P., et al., *Soft tissue knee injury with* 842 843
- 51. Synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis.

52. Sward, P., et al., Soft tissue knee injury with concomitant osteochondral fracture is

53. Sward, P., et al., Soft tissu Steoarthritis Cartilage, 2012. 20(11): p. 1302-8.
Sward, P., et al., *Soft tissue knee injury with concomitant osteochondral fracture is*
associated with higher degree of acute joint inflammation. Am J Sports Med, 2014. 42 844 Osteoarthritis Cartilage, 2012. **20**(11): p. 1302-8.

845 52. Sward, P., et al., *Soft tissue knee injury wis*

846 *associated with higher degree of acute joint infle*

847 1096-102.

848 53. Garriga, C., et al., *Cli* 845 846 847
- For associated with higher degree of acute joint inflammation. Am J Sports Med, 2014. 42(5): p.

1096-102.

Garriga, C., et al., Clinical and molecular associations with outcomes at 2 years after acute

knee injury: a lon associated with higher degree of acute joint inflammation. Am J Sports Wied, 2014. 42(5): p.
1096-102.
Garriga, C., et al., Clinical and molecular associations with outcomes at 2 years after acute
knee injury: a longitudin -------
Garriga, C.
knee injury
Rheumato
Asghar, S.,
Rheumato 848 For all the injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK). Lancet

Rheumatology, 2021. 3(9): p. E648-E658.

Asghar, S., et al., *Exosomes in intercellular communication and implications for* 849
850
- 851 852
- Rheumatology, 2021. 3(9): p. E648-E658.
Asghar, S., et al., *Exosomes in intercellular communication and implications for osteoarthritis.*
Rheumatology (Oxford), 2020. 59(1): p. 57-68.
Withrow, J., et al., *Extracellular v* 853
- 850 Rheumatology, 2021. 3(9): p. E648-E658.
851 54. Asghar, S., et al., *Exosomes in intercellular*
852 Rheumatology (Oxford), 2020. 59(1): p. 5
853 55. Withrow, J., et al., *Extracellular vesicles*
854 *osteoarthritis.* A Rheumatology (Oxford), 2020. 59(1): p. 57-68.

55. Withrow, J., et al., Extracellular vesicles in the pathogenesis of rheumatoid arthritis and

osteoarthritis. Arthritis Res Ther, 2016. 18(1): p. 286.

Helfand, B.T., et al Withrow, J., et al., *Extracellular vesicles in t.*
 Mithrow, J., et al., Extracellular vesicles in t.
 osteoarthritis. Arthritis Res Ther, 2016. **18**(1): p.

Helfand, B.T., et al., *A Novel Proteomics Appro

<i>and Path* osteoarthritis. Arthritis Res Ther, 2016. 18(1): p. 286.

56. Helfand, B.T., et al., A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers

and Pathways that Associate with Lower Urinary Tract Symptoms in Me 854 osteoarthritis. Arthritis Res Ther, 2016. 18(1): p. 286.
855 56. Helfand, B.T., et al., A Novel Proteomics Approach to
856 and Pathways that Associate with Lower Urinary Tra
857 Results of the Symptoms of Lower Urinary 855 and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot
Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study.
Urology, 2019. 129: p. 35-42.
57. Russell, T.M 856 857
- Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study.
Urology, 2019. 129: p. 35-42.
Russell, T.M., et al., Potential of High-Affinity, Slow Off-Rate Modified Aptamer Reagents for
Mycobac Results of the Symptoms of Nycobacterium tuberculosis Proteins as Tools for Infection Models and Diagnostic Applications. J Clin Microbiol, 20 859 860 861
- 858 Urology, 2019. 129: p. 35-42.
859 57. Russell, T.M., et al., *Potential*
860 *Mycobacterium tuberculosis*
861 *Applications.* J Clin Microbiol,
862 58. Dammer, E.B., et al., *Multi-pl*
863 *fluid and plasma reveals*
86 Mycobacterium tuberculosis Proteins as Tools for Infection Models and Diagnostic
Applications. J Clin Microbiol, 2017. 55(10): p. 3072-3088.
Dammer, E.B., et al., Multi-platform proteomic analysis of Alzheimer's disease ce Applications. J Clin Microbiol, 2017. 55(10): p. 3072-3088.
Dammer, E.B., et al., *Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal*
fluid and plasma reveals network biomarkers associated with proteos Applications. J Clin Microbiol, 2017. 35(10): p. 3072-3088.
Dammer, E.B., et al., *Multi-platform proteomic analysis of*
fluid and plasma reveals network biomarkers associ
matrisome. Alzheimers Res Ther, 2022. 14(1): p. 17 862 58. Dammer, E.B., et al., *Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal*

fluid and plasma reveals network biomarkers associated with proteostasis and the

matrisome. Alzheimers Res Ther, 2022. 863
- 864 matrisome. Alzheimers Res Ther, 2022. 14(1): p. 174.
865 59. Candia, J., et al., Assessment of variability in the plas
866 Rep, 2022. 12(1): p. 17147.
867 60. Liu, R.X., et al., Comparison of proteomic methods in
868 i 865
- matrisome. Alzheimers Res Ther., 2022. 14(1): p. 174.
Candia, J., et al., Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci
Rep. 2022. 12(1): p. 17147.
Liu, R.X., et al., Comparison of proteomic met 59. Candia, J., et al., Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci
Rep, 2022. 12(1): p. 17147.
60. Liu, R.X., et al., Comparison of proteomic methods in evaluating biomarker-AKI associations
 867
- 869
- 866 Rep, 2022. 12(1): p. 17147.

867 60. Liu, R.X., et al., Comparison

868 *in cardiac surgery patients.*

869 61. Raffield, L.M., et al., Com

870 *Studies.* Proteomics, 2020. 2

871 62. Anderson, J.R., et al., Opt

872 in cardiac surgery patients. Transl Res, 2021. 238: p. 49-62.

61. Raffield, L.M., et al., Comparison of Proteomic Assessment Methods in Multiple Cohort

52. Anderson, J.R., et al., Optimization of Synovial Fluid Collectio 871
- 868 in cardiac surgery patients. Transl Res, 2021. 238: p. 49-62.
869 61. Raffield, L.M., et al., Comparison of Proteomic Assessme
870 Studies. Proteomics, 2020. 20(12): p. e1900278.
871 62. Anderson, J.R., et al., Optimiz Studies. Proteomics, 2020. 20(12): p. e1900278.

62. Anderson, J.R., et al., *Optimization of Synovial Fluid Collection and Processing for NMR*
 Metabolomics and LC-MS/MS Proteomics. J Proteome Res, 2020. 19(7): p. 2585-870 Studies. Proteomics, 2020. 20(12): p. e1900278.

871 62. Anderson, J.R., et al., *Optimization of Synovia*

872 Metabolomics and LC-MS/MS Proteomics. J Prote

873 63. Ali, N., et al., *Proteomics Profiling of Human*

8 Metabolomics and LC-MS/MS Proteomics. J Proteome Res, 2020. 19(7): p. 2585-2597.

Ali, N., et al., Proteomics Profiling of Human Synovial Fluid Suggests Increased Protein

Interplay in Early-Osteoarthritis (OA) That Is Los Metabolomics and LC-MS/MS Proteomics. J Proteome Res, 2020. 19(7): p. 2585-2597.

873 63. Ali, N., et al., Proteomics Profiling of Human Synovial Fluid Suggests Increased

874 Interplay in Early-Osteoarthritis (OA) That Is 873 63. Ali, N., et al., *Proteomics Profiling of Human Synovial Fluid Suggests Increased Protein*

Interplay in Early-Osteoarthritis (OA) That Is Lost in Late-Stage OA. Mol Cell Proteomics,

2022. **21**(3): p. 100200.

64. St 874
- Struglics, A., et al., Technical performance of a proximity extension assay inflammation 875 2022. **21**(3): p. 100200.
876 64. Struglics, A., et al., *Te*
877 biomarker panel with sy 876 biomarker panel with synovial fluid. Osteoarthr Cartil Open, 2022. 4(3): p. 100293.
30 biomarker panel with synovial fluid. Osteoarthr Cartil Open, 2022. **4**(3): p. 100293.
biomarker panel with synovial fluid. Osteoarthr Cartil Open, 2022. **4**(3): p. 100293.
 $\frac{1}{2}$

878 65. Struglics, A., et al., Changes in Cytokines and Aggrecan ARGS Neoepitope in Synovial Fluid
and Serum and in C-Terminal Crosslinking Telopeptide of Type II Collagen and N-Terminal
Crosslinking Telopeptide of Type I Collagen 879 Crosslinking Telopeptide of Type I Collagen in Urine Over Five Years After Anterior Cruciate
Ligament Rupture: An Exploratory Analysis in the Knee Anterior Cruciate Ligament,
Nonsurgical Versus Surgical Treatment Trial. Ar 880 Ligament Rupture: An Exploratory Analysis in the Knee Anterior Cruciate Ligament,
Nonsurgical Versus Surgical Treatment Trial. Arthritis & Rheumatology, 2015. 67(7): p. 1816-
1825. 881 882 Nonsurgical Versus Surgical Treatment Trial. Arthritis & Rheumatology, 2015. 67(7): p. 1816-Nonsurgical Versus Surgical Treatment Trial. Arthritis & Rheumatology, 2015. 67(7): p. 1816-
1825. 883

884

Figure 1. Assessment of the effects of the effects of the effects of each standardisation stap on (A) mean "over any type measured by the SMAsses ment of Pearson correlation coefficients between protein expression in sampl R
re mond
no hy no control.
Se RF
be ch in l spectively. Assessment of Pearson correlation coefficients between protein expression in samples
easured by the SOMAscan platform and by prior immuonossay for nine select proteins across
remultaation steps for (C) OA and (researced by the SOMAscan platform and by prior immunoassay for nine select proteins across
normalisation steps for (C) OA and (D) acute knee injury. The normalisation steps included
hybridisation normalisation (HNI), plat normalisation steps for (C) OA and (D) actue knee injury. The normalisation steps included hybridisation normalisation (HN), plate scaling using plasma calibrators (PS), median signal componibiation (MN) and calibration g hybridisation normalisation (HN), plate scaling using plasma calibrators (PS), median signal
normalisation (MN) and calibration using plasma calibrators (PC). Correlation between the RFUs
(SOMAscan) and absolute concentrat

normalisation (MN) and calibration using plasma calibrators (PC). Correlation between the RFUs
(SOMAscan) and absolute concentrations for the nine proteins across the two methods are shown.
(SOMAscan) and absolute concentr (SOMAscan) and absolute concentrations for the nine proteins across the two methods are shown.
RFUs, relative fluorescence units; %CV, % coefficient of variation; osteoarthritis, OA; Activin A, Inhibin
beta A chain; FGF2, RFUs, relative fluorescence units; %CV, % coefficient of variation; osteoarthritis, OA; Activin A, Inhibeta A chain; FGF2, Fibroblast growth factor 2; IL6, Interleukin-6; IL8, Interleukin-8; MCP1, C-C mochemokine 2; MMP3, beta A chain; FGF2, Fibroblast growth factor 2; IL6, Interleukin-6; IL8, Interleukin-8; MCP1, C-C motif
chemokine 2; MMP3, Stromelysin-1; TGFβ1, Transforming growth factor beta-1; TIMP1, Tissue
inhibitor of metalloprotein beta A chain; FGF2, Fibroblast growth factor 2; IL6, Interleukin-6; IL8, Interleukin-8; MCP1, C-C motif chemokine 2; MMP3, Stromelysin-1; TGFβ1, Transforming growth factor beta-1; TIMP1, Tissue
inhibitor of metalloproteinase 1; TSG6, Tumor necrosis factor-inducible gene 6.

 $\frac{1}{2}$ is the strong strong strong metalloprote inhibitor of metalloproteinase 1; TSG6, Tumor necrosis factor-inducible gene 6.

Figure 2. (A) Variation explained (%) by the top 10 PCs derived from the standardised log abundance proteomic data. (B) Correlation between PC1 and protein abundance, with two high-abundance proteins (albumin, a soluble serum protein, and LDH, an intracellular protein) marked. Protein abundance is calculated as the standardized RFU for each protein adjusted by the protein's dilution factor used in the SomaScan assay (the "dilution bin"). (C) Comparison of variation explained (%) by PC1 between 18 pairs of SF samples that were centrifuged (spun) or not (unspun) after aspiration and prior to freezing, with paired samples from the same participant joined by separate lines. Red lines show samples that had an increased PC1 prior to spinning, and the green line where it was decreased. Correlation between PC1 and intracellular protein score (D) before and (E) after IPS adjustment. (F) Variation explained by the top 10 PCs derived from the batch corrected and IPS adjusted log abundance proteomic data. In all cases, correlation is measured using the Pearson correlation coefficient. IPS, Intracellular Protein Score; PC, principal component; LDH, Lactate dehydrogenase.

Figure 3. (A) Distribution of the second principal component (PC2) derived from the standardised log Figure 3. (A) Distribution of the second principal component (PC2) derived from the standardised log
abundance data, showing a bimodal distribution. (B) UMAP visualisation of two reduced dimensions
(D1 and D2) of the top (D1 and D2) of the top PCs of the standardised log abundance data. (C) Example of a strongly bimodal protein measurement, TSG101, RFU (y-axis) against Oxford laboratory processing order (x-axis) and coloured by laboratory bimodal protein measurement, TSG101, RFU (y-axis) against Oxford laboratory processing order (x-
axis) and coloured by laboratory processing batch (with only points within the same processing batch
axis) and coloured by la axis) and coloured by laboratory processing batch (with only points with only points with \sim

when processing batch changed, and only rarely within processing batch. This effect was particularly around a mong sample batches that were processed and re-assayed, showing the independent SF samples before [original] and strong among sample batches that were processed later in processing order. (D) The same example processed and re-assayed, showing that bimodal status changed after laboratory re-processing. (E) processed and re-assayed, sh protein measurement for three independent SF samples before [original] and after they were re-
processed and re-assayed, showing that bimodial status changed after laboratory re-processing (E)
Distribution of PC2 denved fr Distribution of PC2 derived from standardised log abundance data, showing the two probability
clensity functions of the Gaussian Mixture Model used to cleasify samples into the two bimodal signal
status groups. (F) UMAP vi density functions of the Gaussian Mixture Model used to classify samples into the two bimodal signal standardised (by IMAP visualisation of two reduced dimensions (D) Land D2) of the top PCs of the backmanical standardised status groups. (F) UMAP visualisation of two reduced dimensions (D1 and D2) of the top PCs of the Gaussian disate (S) above and the interred bimodal signal status. (G) it integram of PC2
of the batch corrected log abundanc standardised log abundance data, colored by the inferred bimodal signal status. (G) Histogram of PC2 of the batch corrected dig abundance data, with the now near-identical distributions of the two reduced bimodal signal st of the batch corrected log abundance data, with the now near-identical distributions of the two bimodal signal status. (G) abundance data, in the inferred big abundance data, in the inferred bimodal signal status. (G) of t bimodal signal status groups shown as colored lines, [H] UMAP visualisation on two reduced
dimensions [O1 and D2] of the top PCs of the batch corrected log abundance data, colored by the normations [O1 and D2] of the batch dimensions (D1 and D2) of the top PCs of the batch corrected log abundance data, colored by the inferred bimodal signal status. RFUs, relative fluorescence units; PC, Principal Component; TSG101, Tumor susceptibility gene inferred bimodal signal status. RFUs, relative fluorescence units; PC, Principal Component; TS6101,
Tumor susceptiblity gene 101 protein; UMAP, Uniform Manifold Approximation and Projection.
Tumor susceptiblity gene 101 pr inferred biling and status. RFUs, relative fluorescence units; PC, Principal Approximation and Projection.
Tumor susceptibility gene 101 protein; UMAP, Uniform Manifold Approximation and Projection. Tumor susceptibility gene 101 protein; UMAP, Uniform Manifold Approximation and Projection.

Free records in the control of the control Figure 4. Consideration between Sometical Figure 1. Correlation and the system of the system of the system of SOMAscan data processing, for (A) osteoarthittis and (B) actual facence injury samples. Correlation was measured SOMAscan data processing, for (A) osteoarthritis and (B) acute knee injury samples. Correlation was measured using the Pearson correlation (B) acute knee injury samples. Correlation was measured using our stages of the dat measured using the Pearson correlation coefficient. Raw data refers to the raw RFUs without any
processing, optimised standardistion was the data standardised using correlated polimial
processing, optimised standardistion processing, optimised standardisation was the data standardised using our selected optimal
normalization steps (Figure 1), processed without IPS adjustment refers to data that has been bach
corrected for bimodal ignal sta promunised standardisation and processed with corrected for bimodal signal status and plate but not IPS adjusted, and processed with IPS
adjustment refers to samples that have undergone both batch correction and IPS adjustment. IPS,
Intracellular Protein Score; Protei adjustment refers to samples that have undergone both batch correction and IPS adjustment. IPS,
Intracellular Protein Score; Protein name abbreviations as in Figure 1.
District and processed with IPS and processes in Figur lntracellular Protein Score; Protein name abbreviations as in Figure 1.

Advanced both batch correction and IPS adjustment. IPS, and IPS adjustment. IPS, and IPS adjustment. IPS, and

IPS, and IPS, and IPS, and IPS, and IP Intracellular Protein Score; Protein name abbreviations as in Figure 1.

Which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.14.23294059;](https://doi.org/10.1101/2023.08.14.23294059) this version posted August 16, 2023. The copyright holder for this preprint

|
| F << < < +
| F << + |
| F <
| f ||
| F <
| (Figure 5. Overview of the final data processing and quality control pipeline for synovial had
SOMAscan data used by the STEpUP OA consortium, broken down into three stages: standardisation
(yellow box), technical confounde (yellow box), technical confounder correction (blue box) and filtering (green box). More details on
filtering thresholds, and the number removed by each filter, can be found in Supplementary Table S4.
Intering thresholds, f is the box), technical conformation correction (blue box), and intering (green box), and the conformation on f is the filtering thresholds, and the number removed by each filter, can be found in Supplementary Table filtering thresholds, and the number removed by each filter, can be found in Supplementary Table S4.
The number removed by each filter, can be found in Supplementary Table S4.
The number of the number of the number of the

 Figure C. visualisation of selected predefined confounders against select pincipal conforted predefined, (FS adjusted dist. (A) The average value of PC9 (most strongly associated with plate position) by sample well positio with plate position) by sample well position, (B-F) visualisation of the two PCs most strongly
associated with each confounder, coloured by confounder value. Pre-defined confounders shown are
associated with each confounde associated with each confounder, coloured by confounder value. Pre-defined confounders shown are possed by independent of the sample in version assessed by visual inspection, (C) volume of the two PCs most strongly approac (B) blood staining grade of sample after aspiration assessed by visual inspection, (C) volume of sample taken during aspiration, (D) age of the sample in years, measured from aspiration to sample reacessing at Oxford, (E) (Sample taken during aspiration, [D] age of the sample in years, measured from aspiration to sample processing at Oxford, [E] the number of times the sample was thawed and re-frozen before sample processing at Oxford, [E] processing at Oxford, (E) the number of times the sample was thaved and re-frozen before sample
processing at Oxford, (E) the disease group of the sample (osteoarthritis [OA], acute knee injury
[Injury], healthy control, i processing at Oxford, (F) the disease group of the sample (osteoarthritis [OA], acute knee injury
[Injury], healthy control, inflammatory arthritis control].
[Injury], healthy control, inflammatory arthritis control]. procession at Oxford, inflammatory arthritis control).
 $\begin{pmatrix} \text{Injury} \end{pmatrix}$, healthy control, inflammatory arthritis control). [Injury], healthy control, inflammatory arthritis control).

 F and F a Figure 7. UMAP, the dimension of two reduced winds of two reduced dimensions (D1 and D2) of the top PCs of two reduced dimensions (B1 and D2) of the top, coloured by fisears group. These groups were oteocrathritis (OA, scu disease group. These groups were osteoarthritis (OA, acute knee injury [injury], healthy controls, inflammatory arthritis controls.
Inflammatory arthritis controls.
UMAP, Uniform Manifold Approximation and Projection. disconsisted groups were osteocratic controls.
Inflammatory arthritis controls,
UMAP, Uniform Manifold Approximation and Projection.

inflammatory arthronough arthronough the UMAP, Uniform Manifold Appro UMAP, Uniform Manifold Approximation and Projection.